

# Royal Jelly, Bee Brood: Composition, Health, Medicine: A Review

Stefan Bogdanov

*For so work the honey-bees  
Creatures that by a rule in nature teach  
The Act of order to a peopled kingdom.  
They have a king and officer of sorts.*

Shakespeare, King Henry V

The ancient Egyptians knew royal jelly (RJ) and believed royal jelly will keep the pharaoh's body young and beautiful even after he passes away to the other life. They put royal jelly next to his body, among the most precious golden items and royal jewels. They also used jelly to prepare the mummy. Cleopatra used it for her cosmetics in order to keep herself beautiful. The ancient Chinese used royal jelly as a aphrodisiac<sup>194</sup>.

You can find more information on the production, collection and quality and applications forms of RJ in the illustrated Royal Jelly Online Books, on [www.bee-hexagon.net](http://www.bee-hexagon.net).

## COMPOSITION

Royal jelly is a viscous jelly substance. It is partially soluble in water with a density of 1.1 g/mL. Its colour is whitish to yellow, the yellow colour increasing upon storage. Its odour is sour and pungent, the taste being sour and sweet. The sensory characteristics are an important quality criteria. Old royal jelly, which has not been properly stored tends to be darker and a rancid taste can develop. For optimum quality it should be stored in frozen state. The viscosity varies according to water content and age - it slowly becomes more viscous when stored at room temperature or in a refrigerator at 50C. The increased viscosity appears to be related to an increase in water insoluble nitrogenous compounds, together with a reduction in soluble nitrogen and free amino acids<sup>231</sup>. These changes are apparently due to continued enzymatic activities and interaction between the lipid and protein fractions.

There are no royal jelly international standards. However, some countries like Brazil, Bulgaria, Japan and Switzerland have established national standards. A working group of the International Honey Commission, headed by Sabatini, is working on the elaboration of an international standard. A first work in view of establishment of a standard has been published<sup>202</sup>

### Composition of royal jelly after<sup>202</sup>

	Fresh	lyophilized
Water %	60 - 70	< 5
Lipids %	3 - 8	8 - 19
10-hydroxy-2-decenoic acid %	> 1,4	> 3,5
Protein %	9 - 18	27 - 41
Fructose + glucose+ sucrose %	7 - 18	-
Fructose %	3 - 13	-
Glucose %	4 - 8	-
Sucrose %	0,5 - 2,0	-
Ash %	0,8 - 3,0	2 - 5
pH	3,4 - 4,5	3,4 - 4,5
Acidity (ml 0.1N NaOH/g)	3,0 - 6,0	-

## Humidity

The water content with 60-70 % is the main component of royal jelly. The dry substance is composed of carbohydrates, proteins, amino acids and fat. Smaller quantities of minerals and vitamins are also present (see table).

## Proteins and peptides

with 17 to 45 % of the RJ dry weight are the main substance class of RJ<sup>134</sup>. They are the main nitrogenous substances, accounting for about 97-98 % of them<sup>133</sup>. About 60 % of them are water-soluble<sup>133</sup>. 82-90 of the RJ proteins belong to the Major Royal Jelly Protein type (RRJP) protein<sup>208</sup>. This protein belongs to the albumin protein class<sup>219</sup> and has immuno-modulating activity<sup>181</sup>. An antibacterially active protein, called royalisin has also been characterised<sup>56</sup>. Different glycoproteins have also been found<sup>105-108, 167, 252, 269</sup>. Different peptides have been characterised: apisimin<sup>14</sup>, one with antihypertensive activity<sup>161, 162</sup> and so called jelleines with antibacterial properties<sup>53</sup>. A number of enzymes have been characterised: glucose oxidase<sup>11, 203</sup>, invertase<sup>11, 238</sup>, acid and alkaline phosphatase, alpha and beta esterase, leucine aminopeptidase, valin aminopeptidase lipase, phosphoamidase,<sup>238</sup> and superoxide dismutase<sup>103</sup>.

Free amino acids represent only 0.6-1.5% , the majority of which belong to the L series. The most representative are proline and lysine<sup>29, 209</sup>. Upon storage at 4°C for 10 months no significant changes of amino acids were encountered, while after room temperature storage proline and lysine content increased<sup>29</sup>. This is due probably to proteolytic enzyme activity.

## Lipids

The Lipids with 3 to 19 % of the RJ dry weight<sup>29, 136</sup>, are, second in importance after the proteins. 80 to 90 % of the lipid fraction consists of free fatty acids, the rest being neutral lipids, sterols, hydrocarbons<sup>109, 134, 136, 138, 139</sup>.

Most of the organic acids are free with rather unusual structure rarely encountered in nature, mono- and dihydroxy acids and dicarboxylic acids with 8 and 10 carbon atoms<sup>135, 136</sup>. The identification of this fraction – in particular as regards the pattern and quantitative analysis of free organic acids – is believed to represent the criteria of choice for defining the genuineness of RJ<sup>28, 33</sup>. The main acid 10-hydroxy-2-decenoic (HDA) is an unsaturated acid, which is determined for the evaluation of RJ genuinity (see Quality parameters and Standard)

HDA and also the other fatty acids of RJ have antibacterial properties<sup>165, 213</sup>, thus contributing to the relatively low content of bacteria in this product.

The other fatty acids are all saturated mono- and dihydroxy-, mono- and dicarboxylic acids have not been quantified exactly can be roughly estimated to be around 0.5 to to 1 g/ 100 g<sup>138</sup>

## Carbohydrates

are third in importance, composed of mainly fructose, glucose and sucrose<sup>137, 140, 211</sup>, with some traces of maltose, trehalose, melibiose, ribose and erlose also being found<sup>137, 140</sup>.

## Minerals

Ash content (minerals) represents 0.8 to 3 % of RJ fresh matter.

The major elements are K, P, S, Na, Ca, Al, Mg, Zn, Fe, Cu and Mn but there are trace amounts (0.01-1 mg/100 g) of Ni, Cr, Sn, W, Sb, Ti and Bi. The sodium content of RJ varies between 11 and 14 mg/ 100 g.<sup>225</sup>

## Vitamins

The concentrations of vitamins in RJ are distributed over a broad spectrum; vitamins showing fairly uniform values are riboflavin, thiamine, niacin and folic acid. Likewise present but with greater variations are pyridoxine, biotin, pantothenic acid and inositol.

Only traces of vitamine C are present, while the fat soluble vitamins like vitamine A, D, E and K are absent<sup>207</sup>.

## Other minor components

Numerous minor compounds, belonging to diverse chemical categories, have been identified in royal jelly. Among these are two heterocyclic substances, biopterine and neopterin at 25 and 5 ijg/g of fresh weight respectively<sup>200</sup>. These compounds are found in the food of worker bee larvae too, but at about one tenth of these concentration. Other substances identified include several nucleotides as free bases (adenosine, uridine, guanosine, iridin and

cytidine) the phosphates AMP, ADP, and ATP <sup>158</sup>, acetylcholine (1 mg/g dry weight, <sup>79</sup> and gluconic acid (1.4 % of fresh weight, <sup>173</sup>. Benzoic acid (8-15 mg/kg) has also been found <sup>164</sup>. Small amounts of malic, lactic and citric acid have also been found <sup>102</sup>.

## ROYAL JELLY AS A NUTRIENT

Nutritional components of royal jelly, after <sup>202, 210, 251</sup>

	g in 100 g	% RDI (0.2 g per day)	RDI (g/day)
<b>Water</b>	60-70		
<b>Carbohydrates</b> (Fructose, Glucose, Saccharose)	11 - 23	< 0.1	320
<b>Proteins</b>	9 -18	< 0.1	50
<b>Fat</b>	3-8	< 0.1	80

	mg /100g	% RDI for 0.2 g RJ	RDI* (mg/day)
<b>Vitamins</b>			
Niacin (B3)	4.5 – 19	< 0.3	15
Pyridoxin (B6)	0.2 – 5.5	< 1	1.4
Thiamin (B1)	0.1 – 1.7	< 1	1.1
Riboflavin (B2)	0.5 – 2.5	< 1	1.3
Pantothenic acid	3.6 – 23	< 1	6
Folic acid	0.01 – 0.06	< 1	0.4
Biotin (H)	0.15 – 0.55	< 0.1 – 2	0.045

<b>Minerals</b>	mg /100g	% RDI for 0.2 g RJ	RDI* (mg/day)
Potassium (K)	200-1000	0.1 – 0.5	2000
Calcium (Ca)	25-85	< 0.1	1000
Magnesium (Mg)	20-100	0.05 – 0.3	350
Zink (Zn)	0.7-8	0.02 – 0.2	8.5
Iron (Fe)	1-11	0.02 – 0.15	12.5
Copper (Cu)	0.33-1.6	0.06 – 0.3	1.2

\*- after the German Nutrition Society

Assuming a daily intake of 2 g per day, the basic nutrients proteins, lipids and carbohydrates contained in RJ (see chapter 1) do not play a role for their RDI. The same is true for the minerals. From the vitamins there is a small contribution of pyridoxin (B6), thiamin (B1), riboflavin (B2) and biotin (H).

## Bio-active ingredients

### HDA and other RJ acids

- antibacterial and immuno activating <sup>10, 15, 17, 152, 165, 213, 259, 263, 269</sup>
- immuno-modulating, anti-cancer <sup>44, 61, 232, 244, 245, 257</sup>
- anti-diabetes <sup>182</sup>

- collagen promoting and skin protecting<sup>112</sup>
- anti-ulcer<sup>49</sup>
- facilitates differentiation of brain cells<sup>75</sup>
- promotes endothelial health, antihypertensive, antihyperlipidemia<sup>90, 163, 264</sup>
- estrogenic<sup>160, 170</sup>
- anti-rheumatic<sup>267</sup>
- activation of TRPA1 and TRPV1 (induces thermogenesis and energy expenditure enhancement)<sup>236</sup>

### **Proteins and peptides**

- anti-oxidative<sup>66, 67</sup>
- immuno-modulating, monocyte-proliferation stimulating<sup>104, 181</sup>
- antibacterial<sup>52, 58</sup>
- anti-inflammatory<sup>111, 153</sup>
- vitalisation and anti-fatigue<sup>97, 220, 221</sup>
- anti-hypertensive<sup>159, 163, 241</sup>
- anti-allergic<sup>181</sup>
- anti-diabetes<sup>113</sup>
- collagen proliferating and skin fibroblast differentiating<sup>247</sup>

### **AMP-N1 Oxide**

- stimulates neuronal differentiation, promotes generation of all three types of cells composing the central nervous system: neurons, astrocytes and oligodendrocytes, against neuronal damage<sup>77, 78</sup>

### **Acetylcholin<sup>260</sup>**

- Nerve transmitter, having a number of hormone-like effects in the central and vegetative nervous system

### **Hormones testosterone, progesterone, prolactine, estradiol (see <sup>256</sup> and p. 17)**

- Increase of male and female fertility, increase of male power and endurance

### **Polyphenols**

- antioxidants<sup>148</sup>

Summarising the above it seems that the unique anti-fatigue and the brain activating properties of royal jelly are mediated by, HAD, by a specific protein and the AMP-N1 oxide.

## **DIETOLOGY AND PROPHYLACTICS**

Royal jelly is a functional food and thus an ideal additive for prophylactic purposes. Due to its ideal effects in newborn children it is an ideal additive to their food. Hovanski (1997) examined the influence of infant nursing food containing also RJ and pollen in comparison with infant food without these ingredients. The infants fed on the food with the ingredients had a better adaptation to stress situations. Krilov and Sokolski prepared a tablet containing 45 mg dry RJ, 30 mg ascorbic acid, the resting 265 mg containing lactose, sucrose, starch and calcium stearate. The authors tested the tablets, given to test students 3 times per day. While there was no influence on normal students, test persons with lowered immunity was beneficially influence, measured by normalised ratios between blood albumin and globulins ratios and the content of A,B, G immunoglobulin proteins and of other parameters<sup>124</sup>.

In summary, RJ has a variety of biological properties which make it an ideal additive with rejuvenating, anti-aging. It can easily be combined with other compounds, vitamins, antioxidants and trace elements.

### **Royal jelly as a supplement for professional sportsmen for better performance**

In a series of test in Russia a Russian preparation Ap-iton 25 was tested in highly trained sportsmen. The tests were carried out at the beginning and after 21 days, the intake of RJ was 4 pills sublingually daily, each one containing 369 mg lactose-glucose absorbed RJ (see page 13), in total corresponding to about 1.2 g dry RJ daily, a control group took placebo. In the tests the resilience of sportsmen was tested in a treadmill, until the sportsmen rejected a further load increase, the load being changed every minute. The endurance of the sportsmen who took the RJ

supplement was significantly better than the controls after 10 and 21 day of the test and remained significant 5 days after the sportsmen stopped taking the supplement. It is known that in physical performance the endurance decreases because of an increase of blood lipid hydroperoxides. An antioxidant as RJ should theretically inhibit the building of the lipid peroxidaton. Indeed, there was a highly significant difference between the test and the control groups regarding this parameter, on the 10<sup>th</sup> and 21<sup>st</sup> day of training, this difference persisted 5 days after stopping supplementation.

It is known that immunity decreases upon persistent physical strain. This results in a decrease of immunogloblins IgA, IgG and IgM. The humoral immunity was tested by measuring these parameters in the blood of the test persons. The IgA concentration in comparison with the initial values was higher than the controls after 21 days, while the change of the other two parameters was not significantly changed. The number of leucocytes, lymphocytes, T-lymphocytes, T-helpers and T-suppressers in the blood are a function of the cell immunity. All of these parameters were significantly higher in the test sportsmen after 21 days, when the values were compared to the initial ones<sup>122</sup>

This preparation is sold in Russia and is accepted as a sport supplement by the Russian Antidoping Agency, see <http://comilfo-api.com/>

A 45% ethanol solution containing 2.4 g native RJ in 100 ml was tested in a sport performance of 17-20 year old female students, who took 3 times 10 drops (approx. 100 mg RJ). Following tests were carried out: measurement of body mass, performance of Stange's breath holding test, measurement of the viso-motoric reaction, hanging on the bars, 30 m runs with maximal speed, measurement of heart rate afterwards, then a 5 minute step test with a step height of 30 cm, 30 climbs per minute followed by a 5 minute rest. There was a significant increase of the reaction of the organism to hypoxia, as measured by the Stange test and an improvement of the viso-motoric reaction<sup>206</sup>.

### **Football players**

In a test with young football players the effect of an intake of a RJ supplement on 13 morphological characteristics in initial and final measuring, tested against a control group (no intake) On the basis of the research results it could be concluded that football players from experimental group who used royal jelly had statistically significant increase of body height and muscle component, and decrease of fat component in final measurement comparing to the initial. Also, the results show statistically significant increase in circumference above knee and circumference of lower leg in experimental group on the end of the experimental treatment. The examinees from experimental group had higher average values in body height, body mass, muscle and bone component, and lower average value in fat component<sup>93</sup>.

## **FUNCTIONAL PROPERTIES**

The significance of royal jelly for human nutrition is relatively small. Only some vitamins play a little role. Assuming that 5 to 10 g per day are consumed, about 1/5 of the recommended daily intake of the present vitamins, mainly of panthothenic acid, can be covered.

The main significance of royal jelly lies in its health-promoting properties. Effects in animals were achieved after injection or ingestion of RJ. Chauvin reviews the biological and pharmacological effects of RJ and states that results are often controversial. He points out that RJ injection is very risky and thus ingestion should be used instead<sup>35,36</sup>. Sublingual application by contact of RJ in order to achieve a direct transmission of RJ into blood is also recommended in order to avoid eventual decomposition of proteins in the digestion tract.

Many East European studies are extensively reviewed in the Krilov and Sokolski RJ monography<sup>124</sup>. Prof. Krilov from the university of Nijni Novgorod has done many original contributions on this topic. The original Russian references will be often referred to as Krilov-Sokolski, as they are not accessible to non-Russian readers.

The main substances responsible for the biological action are 10-HDA and its proteins and peptides. RJ should be conserved in frozen state for best preservation of biological properties.

The different biological effects reported in the literature are compiled in the table below. For better clarity the different effects are summarised according to the type of effect.

### **Antibacterial, antiviral and fungicidal effects**

Many studies have shown that royal jelly has antibacterial activity. These properties have been reviewed. RJ inhibits both gram-positive and gram-negative bacteria, but the first group is stronger inhibited: Antibacterial activity towards different bacteria, many of them pathogenic, has been registered:<sup>224</sup>

The antibacterial activity is due to: *HDA*<sup>17, 213</sup> and to *different proteins and peptides*<sup>53, 57, 224, 262</sup>

Antibiotic resistance increasingly encountered, e.g. against *Pseudomonas aeruginosa* could be overcome by RJ<sup>141</sup>

## Bio-stimulating activity

The role of RJ in the bee colony is to stimulate and increase the growth of larvae, increasing metabolic processes. The most evident effect is the increase of weight of many animals, reported after ingestion of RJ (see table). In an early work it was found in animal experiments that RJ increases oxygen metabolism of tissues and causes increased activity in mice, due to increased concentration and use of blood glucose<sup>64</sup>. RJ increases also tissue oxygen consumption and thus increases performance and endurance. These effects are due to RJ induced increase of respiration and oxidative phosphorylation<sup>124</sup>. The anti-hypoxic, i.e. oxidative effect of royal jelly in animal experiments can be also mentioned here<sup>124</sup>. It was also found that RJ increases the metabolism of humans (especially increased were breathing frequency and basal metabolism<sup>36</sup>).

## Immuno-modulating effects

Immunomodulating effects lay an important effect in cancer, allergy, and inflammation. They can be activating and deactivating. In the case of RJ the activating effects predominate as they have been reported by many workers (see table).

Krilov reports on the increase of all blood cells and the  $\alpha$ -1 and  $\alpha$ -2 globulins fraction after RJ ingestion<sup>124</sup>. The effect on the alpha globulin fraction is probably connected to the reported immunomodulating activity of RJ. RJ induces the formation of T lymphocytes, responsible for the immune response against viruses and cancer cells and also play an important role in inflammation processes<sup>257</sup>. This activity seems to be due to RJ 10-HAD. Tamura et al.<sup>232</sup> showed in experiments with rats that inhibition of tumor growth of slow growing tumors (Ehrlich and Sarcoma strains) is better than that of fast growing ones (leukaemia). Recently the effect of royal jelly was tested on tumour development and metastasis in murine tumour models<sup>185</sup>. RJ did not affect the formation of metastases when given intraperitoneally or subcutaneously. However, synchronous application of tumour cells and royal jelly intravenously significantly ( $p < 0.001$ ) inhibited the formation of metastases.

The immuno-activating effects of RJ are due to its main protein apalbumin<sup>152</sup>. In one case it has been reported that RJ has also immuno-inhibitory anti-allergic effects in mice<sup>181</sup>.

Anti-inflammatory effects, reported for RJ, are hormone-like effects which reduce inflammation. Tissue inflammation is generally thought to be a major cause for body degeneration and ultimate death. Thus, anti-inflammatory compounds are thought to have an anti-aging activity.

## Effects on the nervous system

RJ has also a stimulating, activating effects on the central nervous system, SNS<sup>64</sup>) and also on the vegetative NS<sup>124</sup>. Krilov reports on acetyl-choline like effects on the intestine and on the innervation of the smooth respiration muscle. These effects result in an improved muscle tonus and activity. Intake of Apilac, a Russian preparation based on RJ, leads to an increased phosphorylation of the CNS, to increase of rat brain cholinesterase activity<sup>124</sup>. High doses of 100 mg/kg to mice lead to structural changes of nerve neurons<sup>124</sup>. RJ shows neurotrophic effects on the mature brain via stimulation of GDNF production, and that enhanced expression of neurofilament H mRNA is involved in events subsequently caused by glial cell line-derived neurotrophic factor (GDNF). RJ may play neurotrophic and/or neuroprotective roles in the adult brain through GDNF<sup>72</sup>. Recent brain research has elucidated the mechanism of action for the RJ effects on the CNS. A unique RJ component, cAMP-N<sub>1</sub> oxide, not found in any other materials, acts directly on neuronal differentiation and stimulates the formation of different brain cells<sup>74</sup>. RJ facilitates also the differentiation of all types of brain cells: neurons, astrocytes, and oligodendrocytes<sup>75</sup>. RJ

Royal jelly may be promising for the activation of neural stem cells in a mature brain expected to differentiate into neurons or glial cells. Recent investigations clarified a relationship between the neurogenesis in the dentate gyrus of the hippocampus and the symptoms of depression, expecting efficient use of royal jelly to activate neurogenesis. Reduction of neuronal death and an increase of neurogenesis in Alzheimer's disease and Parkinson's diseases may be also supported by royal jelly, although a detailed animal experiment is necessary<sup>59</sup>.

## Cardiovascular effects

RJ influences different blood parameters: reduction of serum cholesterol and triglycerides levels, increase of high-density lipoprotein-cholesterol levels, lowering of plasma fibrinogen levels and thrombosis (see table). Due to these

effects RJ has cardioprotective effects in physiological and biochemical experiments with mice <sup>124</sup>. Experiments on the isolated heart showed that RJ increased the blood pressure of the heart chamber by 60 %, the maximum velocity of the myocard contraction by 22 and the maximum velocity of the myocard relaxation by 87 %. The coronary blood stream was increased by 42 % and the diastolic blood pressure was reduced by 20 %. These effects are explained by an increased synthesis of bio-energy, ATP in the heart muscle. On the basis of these experiments RJ can be recommended as a cardio-protectant. Krilov reports also on experiments in rats of positive effects of RJ in adrenaline-induced myocarditis <sup>124</sup>. Anti-hypertensive, hypotensive, vasodilatative effects in animals has been reported by different authors (see table).

RJ peptides have been found to have an anti-hypertensive activity<sup>163</sup>

### Other effects

Other biological effects have been also reported (see table below)

- Anti-oxidative and radiation-protective and hepatoprotective (liver-protecting)
- Hyperglycaemic, preventing insulin resistance
- Stimulating bone formation and promoting bone healing in rabbits, preventing osteoporosis in rats
- promoting building of collagen in cell cultures
- suppressing the development of atopic dermatitis-like skin lesions in rats

### Biological and pharmacological effects of royal jelly in animal and cell culture experiments

Effect	References
<b>Antibacterial, fungicidal, antiviral, antiparasitic effects</b>	
Antibacterial	1, 10, 57, 82, 82, 83, 83, 131, 212, 224, 262, 268
Fungicide	205, 224
Antiviral	40, 224
Active against various parasitic <i>Trypanosomidae</i>	147
<b>Bio stimulatory effects, anti-aging</b>	
Estrogenic and gonadotropic effects in cells and in rats	81, 166, 226
Increases growth and weight of chickens, turkeys, ducks, rabbits, guinea-fowls, pigs, calves, guinea pigs, mice and rats	18-27, 35, 38
Anti-fatigue, increases activity improves its resistance to stress	81, 97, 124
Increases reproduction capacity of rats and sheep	84, 85, 100, 118, 119
Increases oxygen consumption in tissues in vitro, antihypoxia	64, 124, 192
Against infertility of male rabbits, improves sexual efficiency in rats and hamsters	46, 73, 110
Life-prolonging in mice	88
<b>Immuno-modulating effects: anti-cancer, anti-allergy and anti-inflammatory</b>	
Immuno-stimulating activity in animals or in cell cultures, increase of leucocytes count	6, 47, 61, 124, 126, 157, 180, 181, 218, 227, 228, 257, 259, 261, 265, 266
Anti-tumor effects in cell culture and animal experiments (ingestion or injection)	16, 39, 42, 176, 184, 185, 232, 243, 246
Inhibits autoimmunity in mice	156
Anti-inflammatory in cell culture tests	111
<b>Cardiovascular effects</b>	
Anti-hypertensive, hypotensive, vasodilatative effects in animals	7, 127, 159, 216, 239, 240, 242
Anti-atherosclerosis: reduces serum cholesterol and triglycerides levels, increases HDL levels, lowers plasma fibrinogen levels and thrombosis	124, 214 37, 199, 215
Cardio-protective in animal experiments, prevents myocarditis	124
Increases blood levels of thyroxine, cortison albumin/globulin ratio and decreases serum proteins after oral administration in rats	35, 36
Increases number of blood cells	124
<b>Effects on the central and vegetative nervous system</b>	
Acts on central nervous activity, activates and protects it. Facilitates the differentiation of brain cells.	64, 74-76, 124
Increases phosphorylation of the CNS to increase of rat brain cholisterase activity	124

Acetyl-choline like effects on the intestine and on the innervation of the respiration smooth muscle	124
Tranquillisation of rats	35, 36
<b>Anti-oxidation, hepatoprotective, radioionprotective</b>	
Anti-oxidative	86, 88, 91, 92, 174, 175
Hepato-protective in animal experiments	124
Reduces stress and terratogenicity, pulmonary edema, hepatic or renal damage in rats due to intoxication with mycotoxins	12, 45
Activates stimulation of hepatocyte DNA synthesis and protects cells from apoptosis, mitogenic effect, prolongs cell proliferation, inhances albumin production.	96, 96, 98, 180
Radiation-protective in animal experiments	63, 191, 258
<b>Other effects</b>	
Prevents osteoporosis in rats and stimulates bone formation	80 177, 254
Skin protection: promotes building of collagen in cell cultures	112
Hyperglycaemic action, prevents insulin resistance, antidiabetic	34, 35, 114, 179, 182
Decreases experimental colitis in rats	99
Suppresses the development of atopic dermatitis-like skin lesions in rats	233

## ROYAL JELLY IN MEDICINE

Royal jelly is especially popular in Asia, see Krell <sup>115</sup>. An important part of the clinical research comes also from Asia. However, the Chinese literature, the biggest producer of RJ of the world, is not accessible to non-Chinese.

Having in mind the many different biological effects of RJ it is difficult to imagine specific medical effects. In the Western World there are only very few clinical studies with RJ. The therapeutic and pharmacological uses of RJ have been summarised in several older reviews <sup>116, 117, 129, 130, 255</sup>, but in these mainly the biological properties of RJ are described, with only very few clinical applications. In more recent Eastern European monographs there are extensive descriptions of the clinical uses of RJ: Shkenderov and Ivanov, 1983<sup>217</sup> Ludyanski, 1994<sup>149</sup>, Krilov and Sokolski, 2000<sup>124</sup>, Asafova et al. 2001<sup>8</sup> and Krylov et al. 2007<sup>122</sup> Many of the clinical applications are taken from these monographs, the original citations were not consulted as they are not accessible to the author. The majority of the cited studies are old and do not stand the criteria for modern clinical tests, i.e. double blind studies with the necessary controls. However they are carried out with a considerable number of patients and in some of the studies control treatments have been carried out. The data summarised here can serve as impetus for further clinical studies.

### Medicinal effects of royal jelly in humans

Use	References
<b>Pediatry:</b> in premature babies or with nutritional deficiencies: improvement of general conditions, increase in weight, appetite, red blood cells and haemoglobin	37, 124, 154, 169, 169, 197, 198, 204, 217
<b>Geriatry:</b> improves general condition and weakness of old people relief of menopausal problems,	41, 124, 149, 217, 229, 255
Against stenocardia and after heart infarct; arteriosclerosis and atherosclerosis; hypertension, hypotension	54, 68, 124, 187, 217, 255
Against respiratory diseases, asthma	124, 128, 129, 217, 223
Against eye diseases, e.g. blepharitis, conjunctivitis and corneal burn, disturbed eye blood circulation;	124, 193, 234
Bio-stimulatory, improves physical performance of humans and resistance to hypoxia	124, 217
Improvement of memory, neuro-vegetative activation	124, 217
Against diabetes	124, 171, 201
Against cancer	95, 266
Against gastric, gastric and duodenal ulcer	89, 124
Improves regeneration of skin in wounds	62
Against degenerative rheumatism	60



Against warts, acne, ulcers, seborrhoe, neurodermitis	124, 125, 155
Against renal disfunction	8

## Pediatry, nursing and geriatry

RJ activates a number of physiological processes and has a stimulating effect on biological growth. Thus its main medicinal use is in podiatry, nursing and geriatry (see tables below). It has a proven effect on the increase of weight of different animals supposes its use in young infants for the same purpose. In the references cited in the table, beneficial effects have been observed in infants with nutritional deficiencies and premature babies or: improvement of general conditions, increase in weight, appetite, red blood cells and haemoglobin.

### Pediatry and Nursing

Author, clinical test, disease	RJ intake, recommendation, results
Lebedeva, 1959, increase of weight and appetite of 1 year old children <sup>132</sup>	Intrarectal intake of 5 mg lyophilized RJ, 3 times a day
Fateeva and Rochal, <sup>50</sup> hypertrophy and lacking appetite of 4 month to 3 years old children	Intrarectal intake of 5 mg lyophilized RJ by smaller children and twice 10 mg sublingual intake by the older ones. 35 children were treated successfully: After 2-3 <sup>rd</sup> day the children began eating, after 15 days the average weight increase was 200 g per day
Iliash <sup>87</sup> , Vasileva <sup>250</sup>	Similar results for similar symptoms as above
Zweer <sup>270</sup>	Similar experiments but with a control group. 25 premature-born children, 30-60 mg RJ was given to the nursing mothers. 76 % of the children recovered, while in the control group the recovery was 46%. The lactation of the 61 % of the nursing mothers (n=93) was improved, while in the control group (n=100) the success rate was 16 %.
Zweer <sup>271</sup>	30 mg pf dry RJ per day was given sublingually to nursing mothers having big blood losses during the birth. Within 8-9 days their blood haemoglobin was normalized.
Magdalena, 1965 <sup>151</sup> . treatment of maldevelopment of breast infants	Comparing the effectivity of different RJ preparations to treat (fresh, lyophilised, RJ in honey) it was concluded that best results were achieved with fresh RJ
Popova, 1960 <sup>195</sup>	RJ was also successfully used in the treatment of Herters intestinal infantilism (disturbance of nutrition in infants)
Destekina, Iliash 1974, after <sup>121</sup>	Successful use of Apilac in new born children with brain trauma
Dmitrieva et al. 1994 after <sup>121</sup>	Use of royal jelly in new born; positive development of the bactericide properties of the skin and elimination of bacterial infections
Gyuzikina 1993, 1998 <sup>69, 71</sup>	In a trial with premature born children with <i>Candidas</i> infections Apilac (contains 10 mg dry RJ) was given for 3 weeks the infections decreased, together with a good weight increase.
Mahmoud 1997 <sup>249</sup>	RJ was given to premature babies in doses of 1 gr per day for 5 days. The babies had a higher weight gain and a higher blood glucose concentration (within limits) than the controls. The authors presume that RJ, and also honey, cause an increased appetite, and thus a higher assimilation of food.

### Geriatry

Author, clinical test, disease	RJ intake, recommendation, results
Different authors, treatment of different geriatric diseases <sup>41, 70, 149, 255</sup>	Effective in the treatment of arteriosclerosis, weakness and menopause
Vitek and Janci, 1968 <sup>217</sup> treatment of poor blood circulation in the brain, local brain damages, Parkinson, astenic and chronic neurosis.	Summary of the experience of several authors treating with RJ different diseases typical for aged persons: 113 patients were examined. 71% of the cases had an improved condition while 13 % experienced complete healing. Best results were achieved in treating weakness while Parkinson was at least influenced.
Valiukiene et al. 1997 <sup>248</sup> , weakness	Intake by 23 volunteers 45 to 89 years old of Apilac tablets containing 70 mg lyophilised RJ, 2 times a day for 25 days: disappearance of dizziness and weakness, improvement of sleep etc.. 74 % of the

persons had a decreased cholesterol, triglyceride content, increased blood counts of immunoreactivity factors

RJ has been successfully used to improve the general condition and weakness due to old age. As sclerosis, weakness, menopause etc. In these treatments, the cardio-protective, anti-atherosclerosis and anti-arteriosclerosis effects of RJ should also play a role. Fujii hypothesises that RJ gamma globulin and gelatine collagen are responsible for the geriatric action of RJ<sup>55</sup>

## Heart and blood circulation diseases

*According to Krylov and Sokolsky and Krylov et al.<sup>122, 124</sup>:*

Nemanov (1959) and Mistenko (1960) used RJ for a successful treatment of stenocardia by sublingual ingestion of 10 mg dry RJ, 3 times a day for 2-4 weeks. The effect of RJ was gradual, complete healing was after 4 weeks, the effects are not immediate like that of nitroglycerine. Nisov and Lupachev (1962) treat successfully stenocardia by treatment with Apilac, the effects are not immediate like nitroglycerine, they are explained by the normalisation of the blood protein pattern.

Kadiseva (1962) report on a successful treatment of arteriosclerosis by treatments of 20-30 mg RJ daily for 40 days.

Zaitzeva and Poryadina (1962) report on the use of Apilac (10 mg dry RJ) twice a day for one month in arteriosclerosis patients. Best results were achieved in patients with initial forms of the disease. Kadiseva (1962) treated successfully arteriosclerosis patients by using 10 day Apilac treatments: initially increasing from 10-20mg, then from 20 to 30 mg, the final two periods decreasing 30-20 and 20-10.

Lupachev (1965) used 3 to 6 pills of Apilac per day to treat 80 persons more than 40 year old myocardial infarct patients, some of them with hypertension. Contrary to the action of nitroglycerine the heart pain was not extinguished, but its duration and intensity decreased. The author presumes an anti-spasmodic action, increase of coronary blood flow and the positive neuro-vegetative effects of RJ to be the cause of the RJ action. The blood tension normalized and the blood parameters improved<sup>150</sup>.

Okorokova and Fomina (1993) was used sublingually 200 dry RJ for 20 days, alone or in combination with anti-stenocardia agents like nitroglycerine. After 2-3 weeks the intake of nitroglycerine could be interrupted or the dose decreased by a factor of 2. The heart dynamic factors as arterial blood pressure and normalisation of EKG improved too.

Okorkov et al. (1993) report in two clinical studies: a) on stenocardia patients and b) of 42-55 years old women with neuro-vegetative-hormonal based myocardial dystrophy using RJ in combination with bee venom. The authors from the cardiology department of the university of Ryazan, Russia, explain the positive effects by the positive hormone-like effects and by the improved nutritional and functional supply of the myocardium.

Lyusov and Meshteryakov (1994) compared the effect of RJ with other anti-stenocardia agents. 300 mg RJ per day was given to all patients with ischemic heart disease (first group) and stenocardia (second group). As whole 76 % of the RJ treated patients had an improvement of the symptoms, best results with 86% success rate was in the group with stenocardia of the second functional class.

Fomina et al. (1998) report on a positive effect of RJ in the treatment of hypotony. 60 patients with blood pressures of 100/60 or less all improved their readings to values of 110/70 to 120/75.

*According to Asafova et al.<sup>8</sup>:*

Margavichene et al. 1988 tested the use of RJ (Apilac, 0.07 g) against ischemic heart disease (including angina pectoris) in 25 men, decrease of cholesterol was achieved only after 5 months.

Dudaev, Ljusov (1988) used RJ against the same disease (0.5 g RJ per day sublingually), resulted in decrease of cholesterol.

Ohotskyi and Kovrigonoi (1984) tested RJ (1-2 tablets of Apilac) in 2141 patients, 412 p. with coronary sclerosis 243 p with stenocardia, 49 p. after myocardial infarct, 384 p. with vegetative vascular dystonia and 384 p. with hypertension climacterium syndrome (men and women). The conclusion of the authors: the general conditions of patients with athero- and coronary cardiac sclerosis with tendency towards vascular spasms improved, stenocardia attacks disappeared, the blood circulation in the limbs improved.

Ogorkov and Fomina (1994) used 10 g honey-royal jelly (2%) for 25 days to treat 20 women with vegetative myocardial dystrophy of women in climacterium. Results: improvement of general condition, blood pressure stabilized.

Positive results on the blood arteriosclerosis and atherosclerosis parameters , cholesterol and triglycerides, were found by Kaczor et al. (1962)<sup>94</sup> and Vittek (1995)<sup>253</sup>, in the latter studies cholesterol was lowered by 14 % in people with moderately high cholesterol levels.

A recent trial by Muenstedt et al. (2009) failed to detect immediate changes of blood lipids after RJ intake<sup>172</sup>.

## Other diseases

### Respiration diseases

*According to Shkenderov and Ivanov<sup>217</sup>:*

Vitek and Janci (1968) have reviewed 10 publications on the use of RJ against bronchial asthma: RJ was used sublingually in doses of 50 to 500 mg per day. Out of 311 patients 75 % showed improvement and the symptoms stopped for a longer time.

Matushevski et al. (1972) treated patients with bronchial asthma with 3 times a day 100-150 mg dry RJ sublingually, for one month. The condition of the patients improved, the eosinophil cell values were back to normal.

Petrov (1971) treated successfully 170 children with spastic bronchitis by aerosol inhalations with honey and RJ.

### Diabetes

Royal jelly contains substances with antidiabetes activity like 10 HDA

Early experiments by Matushevski et al (1972) showed a positive effect of a sublingual intake by 30 patients with sugar diabetes and glomeronephritis of 100 mg dry RJ for 30-40 days: in 18 patients the uric acid concentration decreased by 3 times. In diabetes, caused by insulin antibodies (latent autoimmune diabetes of adults or LADA) the glucose concentration fell from 180 to 140 mg per 100 ml.

Muenstedt et al. (2009) confirmed the RJ antidiabetic effects: twenty volunteers underwent the standardized oral glucose tolerance test (OGTT) and afterwards a second OGTT after ingestion of 20 g of native royal jelly. Serum glucose levels after 2 hours and the area under the curve for glucose were significantly lower ( $P = .041$ ) after royal jelly administration. Substances originating from the pharyngeal glands of the honey bee with insulin-like activity are likely to have caused this effect and may thus be, at least partially, responsible for the lowering impact of honey on blood glucose levels<sup>171</sup>

### Cancer

The anti-tumor effect being tested in children with acute leukaemia, lymphoma and hepatoblastoma. RJ showed some positive results: gain of weight and improvement of the general condition of the children, together with increase of white blood cells, neutrophils and leukocytes. The authors conclude that although RJ can influence positively cancer growth, it is not a drug and patients should not rely on RJ only for treatment of cancers<sup>95</sup>

In another test RJ stimulated the immunoglobulin production by lymphocytes and increased the anti-cancer factors IgM and IgG in patients with breast cancer<sup>266</sup>.

A Russian study by Oveckin in 2004 reported on the successful palliative use of the preparation Apitonus (3 times a 100 mg RJ dose), alone or in combination with chemotherapy and radiation in patients with malignant duodenal ulcers, kidney and glandular cancers. RJ improved the life quality of the patients: their appetite improved and the pains decreased, reported in<sup>120</sup>

### Gastroenterology

Mishtenko (1974) treated patients with gastric and duodenal ulcers and gastritis by 20-25 mg dry RJ 3 times per day for one month, patients being on a diet, a 1. control group on diet only, 2. group with a diet and RJ 3. traditional medication and RJ. In group 1 (diet only) 41 % (40 patients) improved, 66 % of the group 2 patients (n=40) improved while in group three 88 % (130 patients) improved, cited by<sup>124</sup>.

### Wounds and cosmetics

RJ has wound healing properties. Its major protein activates keratinocytes, involved in wound healing<sup>153</sup>. It inhibits the production of proinflammatory cytokines, thought to play a role in skin inflammation<sup>111</sup> and promotes healing in diabetic mice<sup>101</sup>.

The antimicrobial properties, together with the proteins and fatty acids makes it appropriate for skin applications. In cosmetic preparations RJ prevents spots and wrinkles and moisturises the skin<sup>235</sup> A RJ extract increases the natural moisturizing factor (NMF) by promoting the expression of profilaggrin in the skin, as well as by having a moisturizing effect on the stratum corneum<sup>183</sup>.

According to Krylov et al.<sup>122</sup>: Somov and Abramova (1962) used a 5 % RJ aerosol, 2-3 times a day, against seborrhoea and other eczema-like skin inflammations. Many skin creams and lotions contain RJ. Malay et al. (1965) have used of GR against: warts (cream containing 1 % RJ). Smirnova (1960) has used 0.6 % RJ emulsion to counteract face dryness, to improve elasticity of the skin and to diminish pigmentation, to diminish fatty

seborrhoea, to clean the oil glands. Omarov (1990) uses creams with RJ to tonify the face skin, to moisture its dry skin and to make it fresher.

### **Ophthalmology**

According to Krylov et al.<sup>122</sup> RJ has been applied also: in ophthalmology: Maximenko (1975) has used a RJ preparation for the treatment of retina diseases connected with the disturbance of the eye microcirculation. Nedelka et al. (1987-1990) used RJ, 1 % in methylcellulose glycerol) successfully against traumatic keratitis and lesions of the conjunctiva and the cornea. Nedelka et al. developed different preparations: drops, creams and soluble films. These results were confirmed by Takrovski (1974) and Tanev and Peitshev (1974).

### **The experience in Ludyanski's hospital:**

The table below table summarises the different medical uses of RJ while in table the results of treatments with RJ against different diseases in Ludyanski's hospital<sup>149</sup>

<b>Treated disease</b>	<b>Cases Very good and good improvement</b>	<b>Cases with no improvement</b>
Arteriosclerosis	27	6
Cerebral insufficiency	46	12
Climacterium	39	5
Hypertonia	21	8
Hypotony	16	5
Pediatric diseases	12	3
Poor blood circulation	35	11
Sexual dysfunction (men)	26	5

### **Royal jelly for sexual disfunctions and good fertility?**

RJ makes fertile queens out of infertile worker bees. Are there similar effects in vertebrates? In Russian apitherapy RJ has been successfully used in women with climacterium and sexual dysfunction, as mentioned by Ludyanski (see table above).

Zweer (1974) reported also on the the successful treatment of 100 women from 40 to 62 years with climacterium problems. After an intake of twice 20 mg RJ for 2 to 4 weeks the symptoms disappeared in the majority of the patients: hot flashes, sleeplessness and irritability disappeared, work capacity improved<sup>272</sup>.

In a study on the use of RJ against sheep infertility<sup>119</sup> a study was cited, that RJ is used to increase the fertility of men and women<sup>5</sup>. In a book about infertility by R. Lewis, it is claimed that said to improve fertility in both men and women, in men by increasing the quality of their sperm, and in women by increasing the quality of their eggs<sup>146</sup>.

An intravaginal application of mixture of honey and royal jelly was successful for treating male factor infertility (asthenozoospermia)<sup>4</sup>, and also of treating female infertility by a collagen-like promoting action on fetal membranes<sup>2</sup>.

As RJ has estrogenic and proven effects to increase animal fertility (see table on p 4) it could also influence positively human fertility.

## **TOXICITY, COUNTER-INDICATIONS AND PRECAUTIONS**

Krylov et al.<sup>122</sup> describes experiments of Vassiliva (1962) and Lupachev (1962, 1976) with animals: doses from 1 to 10 mg per day cause a progressive weight increase stimulation, in a dose of 100 mg/kg the weight increase begins to become smaller and at doses of 1000 mg/kg there is a weight decrease in comparison to controls. The

toxic effect at higher dose is abnormal morphology of the brain tissue of the animals. Spiridonov et al. found no cytotoxic effects for RJ on rat lymphoblast cells<sup>222</sup>.

An injection of 1ml RJ per mice (about 50 g/kg) seem to be toxic, while a dose of 5 g/kg was not toxic and induced an increase of the weight of the lymphatic tissue<sup>65</sup>.

The chronic toxicity of RJ upon ingestion should be further studied, while it seems that RJ ingestion might be toxic in relatively low doses

A good therapeutic index means that the safety factor between the therapeutical and the toxic dose is at least 500 (for most synthetic drugs the TD lies between 3 and 100). In humans a safe dose with a therapeutic index of 500 corresponds to 2 mg RJ per kg, and a therapeutic index for a 75 kg individual this being 150 mg RJ per day. Increasing of this dose to 750 mg per day, RJ will still have an acceptable therapeutical index of 100.

During the last 10 years there are several publications, reporting cases of allergy following the applications of RJ. Asthma and anaphylaxis have been reported in rare cases<sup>3, 43, 188-190, 237</sup>, as well as one case of skin contact dermatitis<sup>230</sup>. These reports are mostly from East Asia, where RJ is consumed more often, while allergy cases in Europe are much less frequently reported. According to an epidemiological study in Hong Kong with 1471 normal persons the allergy prevalence is 6.1 per 1000<sup>142</sup>. Patients with a risk of RJ allergy have often an allergy towards bee venom and are atopic (show immediate allergy reactions)<sup>145</sup>. On the other hand, an epidemiological study in Russia with 640 no cases of RJ were encountered<sup>144</sup>.

RJ should be used as a food-ingredient or medicine only after an allergy test.. For persons with a history of allergies or with asthma, taking royal jelly has caused bronchial spasms, acute asthma and anaphylactic shock. It is therefore imperative that anyone who is considering supplementing with royal jelly consults with a physician before its use, especially those who are allergic to bee stings, honey, or who have asthma. People with bee venom allergy, asthma and with a high incidence of allergy should avoid RJ intake. A special caution should be noted for pregnant and/or lactating women as well as for pregnant and/or lactating women as well as for small children.

## **HEALTH CLAIMS FOR ROYAL JELLY**

According to the EU Regulation 1924/2006<sup>48</sup> different health claims can be made. The claims are classified using the Passclaim project classification of the International Life Science Institute (ILSI)<sup>9</sup>, wherever possible In the Passclaim project the claims are classified into the following subject areas:

1. Diet-related cardiovascular disease
2. Bone health and osteoporosis
3. Physical performance and fitness
4. Body weight regulation, insulin sensitivity and diabetes risk
5. Diet-related cancer
6. Mental state and performance
7. Gut health, digestion and immunity

According to the evidence presented in this review following health claims can be made.

### **1. Diet-related cardiovascular disease**

*Long term ingestion of royal jelly can improve cardiovascular health, concerning the drop of the blood cardiovascular disease risk factors blood lipids and cholesterol*

### **2. Physical performance and fitness**

*Intake of royal jelly can improve the performance and fitness, especially of elderly people (anti-aging)*

### **3. Diet-related cancer**

*Intake of royal jelly can reduce the risk for cancer*

### **4. Mental state and performance**

*Intake of royal jelly can improve the mental state and physical performance. These effects are especially significant in older people (anti-aging effect).*

## INTAKE AND APPLICATION FORMS

Royal jelly is used in different forms: as raw royal jelly (alone or in combination with honey and other bee products, as alcohol extracts in ampules), in lyophilised form or as pills. Most of the natural RJ is stored in frozen state before selling. It is packed often in small, closed, dark coloured bottles, containing 10, 15 or 20 g. Spoilage due to sun light and oxidation is thus prevented. Royal jelly is consumed together with honey or as pills. RJ can be ingested sublingually or directly ingested. Injections are no longer used because of allergy problems.

The daily ingestions dose for adults used in the different studies varies between 10 and 500 mg of fresh royal jelly per day, most human studies are carried out with doses of 20 to 200 mg daily

For apitherapy higher doses are recommended: children 20-100 mg/day; adults: 200-500 mg/day

### Note for applicaton:

*All apitherapy applications of royal jelly should be carried only after consulting a doctor and testing for an eventual allergy People with bee venom allergy, asthma or with a high incidence of allergy should avoid RJ intake. A special caution should be noted for pregnant and/or lactating women as well as for pregnant and/or lactating women as well as for small children. (see 4).*

### **Royal jelly in honey**

For mixing fresh RJ consider honey with a low humidity, lower than 16 % water, in order to prevent spoilage by fermentation. If freeze-dried RJ is added to honey to achieve a higher RJ concentration, crystallised honey with low water content should be used, in order to prevent rising of RJ to the surface. The RJ honey should be stored at lower temperature. One table spoon of about 20 g 1 % RJ in honey of it will contain 200 mg fresh RJ, which equals the recommended dosage per day. It has been reported that HDA content of RJ-honey products decreases upon storage<sup>143</sup>. Thus these products should be stored also at cool temperatures or frozen for optimum activity. In Asia RJ is often an ingredient of beverages.

### **Royal jelly bound in lactose-glucose pills**

According to Burimistrova, the storability of fresh RJ can be improved, similarly to the one of FDB by binding RJ to a glucose-lactose adsorbent according to the following manner: 6 parts of FRJ are added to one part of dried glucose-lactose (1:1), the mixture containing 50 mg/kg L-ascorbic acid as an antioxidant, the mixture is dried until 4 % humidity. This product is stable at 4 to 8 °C for 2 years<sup>31, 32</sup>.

### **Cosmetics**

RJ is often used as an ingredient of cosmetics or for skin application for treatment of burns and other wounds. It is usually included in small dosages (up to 1 %) but it deteriorates quickly. The freeze-dried form should be used because it is easier to handle and is more stable.

Facelifting cream with RJ (found in [www.royalbeejelly.net](http://www.royalbeejelly.net)):

- 80 grams of blended oil; 45 grams of cocoa butter; 15 grams of beeswax; 1,5 dcl of water; 10 grams of fresh royal jelly
- Melt the oils and wax at low heat, stirr for 12 minutes, remove the melted liquid from the stove and add water, mix with a mixer (handy one) until it gets creamy like – smooth, poar into a glass, cover and store on a dark place. See recipes for other RJ cosmetic products in [Krell](#)<sup>115</sup>

## **BEE BROOD FOR NUTRITION AND HEALTH**

### **Composition and nutritional requirements**

The composition of fresh bee larvae has been studied only by Finke<sup>51</sup>, while the composition of powdered bee larvae is studied by Narumi<sup>178</sup>. There is quite a good agreement for the bee larvae composition between these two studies excepting for biotin. Bee larvae could be used in bigger quantities as a part of the food diet. As shown in the table bee larvae is a good protein source, especially of essential amino acids for human nutrition. The fatty acids are mostly saturated (52 %), monoansaturated acids being 46 % and poly-unsaturated acids only 2 % three primary fatty acids are oleic, palmitic and stearic acids. Indeed, the greater part of the protein is composed of amino acids. Of all amino acids only sulphur amino acids methionine and cysteine are lacking. It is a good source of vitamine C, choline, inositol, and most of the B vitamins, while it contains no detectable levels of fat-soluble

vitamins. It is also a good source of minerals, from all trace elements the content of Selenium being most noteworthy.

Budnikova (2009) found that fresh drone brood contains 2.73 % 10-HDA 8 nMoles/l testosterone and 2745 nMoles/l estradiol<sup>30</sup>.

### Composition of bee brood compare to that of beef and soybean, after<sup>115</sup>

Component	larvae	pupae	beef	soybean
Water	77	70.2	74.1	70.0
Protein	15.4	18.2	17.7	12.9
Fat	3.7	2.4	2.8	5.9
Glycogen*	0.4	0.8	0.1-0.7	2.4

\*- glycogen (a carbohydrate polymer) was determined instead of sugar, contained as 9 % of total, which originates from honey rests.

Besides a possibility to be used as food for its protein content, it could also have similar effects like RJ. However, there are very few published works. Italian psychiatrists observed improvements in respect to the appetite, body weight, hepatic activity, digestion and haemophoretic functions of 15 female psychiatric patients who were suffering from loss of weight and appetite<sup>168</sup>.

Drone brood, after addition of a little propolis, was desiccated under vacuum until 99 % dry matter concentration. The product kept the original biological properties, measured by its immunomodulating, spleen and T-cell stimulating properties<sup>196</sup>.

### Main components of fresh<sup>32, 51</sup> and powdered<sup>178</sup> bee brood

Component	Fresh g/100 g	Powdered g/100 g	RDI g
Water	76.8	4.5	
<i>Proteins total</i>	9.4	52.3	48-56
(Amino acids)	7.9	57.7	
<i>Lipids</i>	4.7	21.9	
Fatty acids	4.0		
10-HDA	3.3		
<i>Carbohydrates</i>	8	17.8	300-340
Fiber content	0.5		
Ash content	0.8	3.5	

### Secondary components of fresh<sup>32, 51</sup> and powdered<sup>178</sup> bee brood:

Component	Fresh	Powdered	RDI
<b>Vitamins</b>	mg/kg	mg/kg	mg
Vitamin A (IU/kg)	< 1000		
β-Carotene	< 0.2		
Vitamine E (IU/kg)	< 5		
Vitamine C	38		
Vitamine B <sub>1</sub> Thiamine	4.1	16.9	1.4
B <sub>2</sub> ; Riboflavin	9.1	31.2	1.6
B <sub>3</sub> ; Niacin	36.7		18
Folic acid		0.93	0.4
B <sub>5</sub> ; Pantothenic acid	11.9	51.5	6
B <sub>6</sub> ; Pyridoxin	1.2	1.8	2
B <sub>12</sub>	< 1.2	0.31	6 μg
H; Biotin (μg/kg)	0.23	776	30 μg
Choline (g/kg)	1.68	6.9	0.5
Inositol (g/kg)		10.5	30 mg



Minerals	mg/kg	mg/kg	mg/kg
Sodium	128	423	2400
Potassium	2690	10400	3500
Magnesium	211	816	350
Calcium	138	446	1000
Phosphorus	1790	8040	1000
Iron	16	63.2	15
Manganese	0.6	3.3	5
Copper	4	16.9	2
Selenium	0.06	0.12	35 µg

### Hormones in fresh royal jelly and fresh drone brood<sup>32</sup>

	Fresh royal jelly	Fresh drone brood
	nmoles /100 g	nmoles /100 g
Testosterone	0.20 ± 0.03	0.31 ± 0,015
Progesterone	4.61 ± 0.26	51.32 ± 8.69
Prolactine	70.8 ± 20,0	410.0 ± 65,4
Estradiol	52.0 ± 6,0	677.6 ± 170,3

Besides these hormones Burismistrova reports on Chinese studies by R.G.Li et al. (1982) и Pan Jian-Guo (1995) that DB contains also the typical bee hormones as prothoracicotrophic hormone (PTTH), juvenile hormone and ecdyson.

Osintzeva et al. (2009) tested a drone brood (DB) homogenate by feeding 15 mg per kg to 2 years old dogs 20 min. before the regular feeding. The dogs ate voluntarily the DB. Blood was tested before and 30 days after intake. : Thyroxin (Tx) and tri-iodotironine (Ti) concentrations increased by 40 %, while thyretropic hormone (Th) concentration decreased by 37 %, total blood proteins increased by 12 %, triglycerides increased by 99 %, high density lipoproteins increased by 12 % and low density lipoproteins by 94 %. The weight increase was 92 % higher than that of the controls<sup>186</sup>.

### Bee brood for human consumption after [Krell](#)<sup>115</sup>

*Gather larvae by cutting them out from the combs. Refrigerate or freeze or eat immediately. If larvae are refrigerated immediately, freezing, drying, boiling or frying should be completed less than 24 hours after collection of larvae to avoid any spoilage since insect proteins decay much faster than those of beef, chicken, lamb or pork. Where no refrigeration is available, processing will have to be started immediately after collection. If there is no freezer or refrigerator, the boiled larvae should be consumed within a day. Fried larvae will keep a little longer..*

See more information on bee brood in [Krell](#)<sup>115</sup>

### Bee brood in lactose-glucose pills

According to Burimistrova, the storability of fresh bee brood can be improved, by binding fresh BB to a glucose-lactose adsorbent according to the following manner: 6 parts of BB are added to one part of dried glucose-lactose (1:1), the mixture containing 50 mg/kg L-ascorbic acid as an antixodant, the mixture is dried until 4 % humidity. This product is stable at 4 to 8 °C for 2 years<sup>32</sup>.

## Biological action

Burimistrova carried a series of biological experiments. DB shows antibacterial activity, but it is weaker than that of RJ. Mice were fed with: normal feeding without additives (control), with and 10 and 20 mg/kg DB or RJ and were subjected to daily swimming. The animal size of the DB fed mice and the swimming capabilities were less pronounced than after the feeding of the same quantities of RJ, but bigger than the controls. The author concludes that DB has a less pronounced activating and autoprotective activity than RJ, but these activities are more pronounced than the control non treated animals. On the other DB has a more pronounced gonadotropic activity than RJ, allowing the rehabilitation of blood concentration of testosterone and fructose<sup>32</sup>.

Belyaev and Sofonkaya (2009) tested a liquid drone brood by feeding rabbits by intraoral intake of 0.6 ml/kg every 48 hours (controls treated with gelatine). The thiobarbituric reactive substances ( a mass for lipid peroxidation and oxidative stress) decreased by 26 %, while that of the controls increased by 25 %, serum sialic acid concentration (a mass of the cardiovascular mortality risk) decreased in the treated groups decreased by 20 % while the controls it increased by 24 %. The experiments showed a decrease of oxidated reaction products in blood and increase of the cell resistance of the DB treated rabbits. In a second series of experience the endurance of the animals under stress condition was tested by giving 0.015 ml per mouse (controls fed with gelatine) and testing the animals for active swimming after 10 days intake. The endurance of the controls increased by 9 %, that of the DB treated group by 35 % in comparison with the beginning of the test<sup>13</sup>.

## Apitherapy

In Romania a drone brood preparation Apilarnil based on drone brood has been developed and used. It is based on freeze dried drone brood. A Romanian book by N. Iliesu: “Apilarnil – health, power and long life” was published in 1990. Apilarnil is used as a biostimulator for similar conditions as royal jelly: for rehabilitation and activation of the aged people, against neuro-vegetative and sexual problems.

In the Russian book “Theory and agents in apitherapy”, written by a group of Russian scientists, applications against chronic gastric ulcers and liver insufficiency are mentioned, mainly Apilarnil use in Romania. Also Romanian studies of the use of Apilarnil are cited: Ardelianu et al. 1983, reporting on successful use in elderly people with psycho-neurotic symptoms and climacterium related symptoms<sup>122</sup>.

## Allergy

In a study in Russia the incidence of allergy towards DB application was 2.4 % (n=41)<sup>123</sup>.

### References

1. ABD-ALLA, M S; MISHREF, A; GHAZI, I M (1995) Antimicrobial potency of royal jelly collected from queen cells at different larvae ages. *Annals of Agricultural Science* 40 (2): 597-608.
2. ABDELHAFIZ, A T; ABDELMONAEM, J; ABDLERAHMAN, M; OMAR, A; ALY, D (2010) An in-vitro model for the use of Egyptian bee honey and royal jelly in cases of premature rupture of the fetal membranes (PROM), *2nd International Conference on the Medicinal Use of Honey*, IBRA, Kota Bharu, Malaysia, 13.Jan.2010: pp 33.
3. ABDELHAFIZ, A T; ABDELMONAEM, J; ABDLERAHMAN, M; OMAR, A; ALY, D (2010) An in-vitro model for the use of Egyptian bee honey and royal jelly in cases of premature rupture of the fetal membranes (PROM), *2nd International Conference on the Medicinal Use of Honey*, IBRA, Kota Bharu, Malaysia, 13.Jan.2010: pp 33.
4. ABDELHAFIZ, A T; MUHAMAD, J A (2008) Midcycle pericoital intravaginal bee honey and royal jelly for male factor infertility. *International Journal of Gynecology & Obstetrics* 101 (2): 146-149.
5. AL-MASRI, A (2011) The royal jelly. Honeybee kingdom and its derivaton, *In* Bartolome, J A A L F M P (ed.) Arabic Book House Publishers; pp 291-300.

6. AL-MUFARREJ, S I; EL-SARAG, M S A (1997) Effects of royal jelly on the humoral antibody response and blood chemistry of chickens. *Journal of Applied Animal Research* 12 (1): 41-47.
7. ARDRY, R (1956) Royal jelly. I. Physico-chemical and immunological properties. *Annales pharmaceutiques francaises* 14 (2): 97-102.
8. ASAFOVA, N; ORLOV, B; KOZIN, R (2001) *Physiologically active bee products (in Russian)*. Y.A.Nikolaev Nijnij Novgorod; 360 pp
9. ASP, N; BRYNGELSSON, S (2008) Health Claims in Europe: New Legislation and PASSCLAIM for Substantiation. *The Journal of nutrition* 138: 1210S-1215S.
10. BACHANOVA, K; KLAUDINY, J; KOPERNICKY, J; SIMUTH, J (2002) Identification of honeybee peptide active against *Paenibacillus* larvae larvae through bacterial growth-inhibition assay on polyacrylamide gel. *Apidologie* 33 (3): 259-269.
11. BAGGIO, A; DAINESE, N (1998) La qualita della gelatina reale nella conservazione. *Industrie Alimentari* 37 (375): 1290-1294.
12. BDEL-WAHHAB, M A; EL-NEKEETY, A A; ABBAS, N F; EL-KHOLY, W; AMRA, H A; EBAID, A (2006) Efficacy of royal jelly against fumonisin-induced oxidative stress in rats. *TOXICOLOGY LETTERS* 164: S229-S230.
13. BELYAEV, V; SOFONKSAYA, E (2009) Adaptogen properties of drone brood. *Pcelovodstvo* (6)
14. BILIKOVA, K; HANES, J; NORDHOFF, E; SAENGER, W; KLAUDINY, J; SIMUTH, J (2002) Apisimin, a new serine-valine-rich peptide from honeybee (*Apis mellifera* L.) royal jelly: purification and molecular characterization. *Febs Letters* 528 (1-3): 125-129.
15. BILIKOVA, K; WU, G S; SIMUTH, J (2001) Isolation of a peptide fraction from honeybee royal jelly as a potential antifoulbrood factor. *Apidologie* 32 (3): 275-283.
16. BINCOLETTO, C; EBERLIN, S; FIGUEIREDO, C A V; LUENGO, M B; QUEIROZ, M L S (2005) Effects produced by Royal Jelly on haematopoiesis: relation with host resistance against Ehrlich ascites tumour challenge. *International immunopharmacology* 5 (4): 679-688.
17. BLUM, M S; NOVAK, A F; TABER, S (1959) 10-hydroxy-2-decenoic acid, an antibiotic found in royal jelly. *Science* 130: 452-453.
18. BONOMI, A (2001) La gelatina reale nell'alimentazione dei suini in fase di svezzamento. *Rivista di Suinicoltura* 42 (4): 183-188.
19. BONOMI, A (2001) Royal jelly in the feeding of weaning pigs 1850. *Rivista di Suinicoltura* 42 (4): 183-188.
20. BONOMI, A; BONOMI, B M (2000) La gelatina reale nell'alimentazione delle anatre da carne. *Rivista di Scienza dell'Alimentazione* 29 (4): 465-476.
21. BONOMI, A; BONOMI, B M (2000) Royal jelly in duck feeding 1848. *Rivista di Scienza dell'Alimentazione* 29 (4): 465-476.
22. BONOMI, A; BONOMI, B M (2002) La gelatina reale nell'alimentazione dei vitelli in fase de svezzamento. *Apitalia* 29 (9-10;11-12): 45-50.
23. BONOMI, A; BONOMI, B M (2002) Royal jelly in the feeding of calves at the weaning stage 1955. *Apitalia* 29 (9-10;11-12): 45-50.
24. BONOMI, A; BONOMI, B M; QUARANTELLI, A (2000) La gelatina reale nell'alimentazione del coniglio da carne. *Annali della Facoltà di Medicina Veterinaria di Parma* 20: 115-132.
25. BONOMI, A; BONOMI, B M; QUARANTELLI, A (2000) Royal jelly in the feeding of rabbits 1849. *Annali della Facoltà di Medicina Veterinaria di Parma* 20: 115-132.

26. BONOMI, A; BONOMI, B M; QUARANTELLI, A (2001) La gelatina reale nell'alimentazione del tacchino da carne; La gelatina reale nell'alimentazione del faraone da carne. *Rivista di Scienza dell'Alimentazione* 30 (1): 49-60.
27. BONOMI, A; BONOMI, B M; QUARANTELLI, A (2001) Royal jelly in turkey feeding; Royal jelly in guinea-fowl feeding 1851. *Rivista di Scienza dell'Alimentazione* 30 (1): 49-60.
28. BOSELLI, E; CABONI, M F; LERCKER, G; MARCAZZAN, L P; SABATINI, A G; BAGGIO, A; PRANDIN, L (2002) Valutazione di produzioni apistiche: gelatina reale e cera, *In* Sabatini, A G; Bolchi Serrini, G; Frilli, F; Porrini, C (eds) *Il ruolo della ricerca in apicoltura*, Litosei; Bologna; pp 321-329.
29. BOSELLI, E; CABONI, M F; SABATINI, A G; MARCAZZAN, G L; LERCKER, G (2003) Determination and changes of free amino acids in royal jelly during storage. *Apidologie* 34 (2): 129-137.
30. BUDNIKOVA, N (2009) Biologically active compounds in drone brood (in Russian). *Pcelovodstvo* (6)
31. BURIMISTROVA, L; AGAFONOV, A; BUDNIKOVA, N; HARITONOVA, M (2008) Methods for the stabilisation of biologically active components royal jelly (Russian), *Apitherapy today*, Ribnoe, 13.Oct.2008: pp 175-182.
32. BURIMISTROVA, L (1999) Physico-chemical and biological appreciation of drone brood. PhD Ryazan Medical University, Russia; pp. 159pp.
33. CABONI, M F; SABATINI, A G; LERCKER, G (2004) La gelatina reale: origine, proprietà e composizione/Royal jelly:origin, properties and composition. *APOidea* 1: 72-79.
34. CHAUVIN, R (1956) [Principle of royal jelly bees, active on mammalian blood sugar]. *Comptes rendus des Séances de l'Academie des Sciences* 243 (23): 1920-1921.
35. CHAUVIN, R (1968) Action physiologique et therapeutique des produits de la ruche *Traite de biologie de l'abeille*, Masson; Paris; pp 116-154.
36. CHAUVIN, R (1987) *La ruche et l'homme*. Calmann-Lévy, France
37. CHO, Y T (1977) Studies on royal jelly and abnormal cholesterol and triglycerides. *American Bee Journal* 117: 36-38.
38. DAWSON, H; RUBOTTOM, R; HARRIS, L (1962) The effect of administration of royal jelly on the differentiation and growth of newborn rats. *The Anatomical record* 142: 123-129.
39. DEREVICI, A; PETRESCO, A (1959) [Virulicidal action and action on Ehrlich ascites tumor of the hydrosoluble fraction of royal jelly of the honey bee]. *California Medicine* 153: 1720-1722.
40. DEREVICI, A; PETRESCU, A (1960) [Effect of water-soluble extract of royal jelly of the honeybee on various viruses]. *Voprosy Virusologii* 6: 611-614.
41. DESTREM, H (1981) Gelée royale bei älteren Menschen. *Bienenwelt* 23 (6): 149-153.
42. DIOMEDE-FRESA, V; LA PESA, M; RESTUCCIA, P (1966) [Influence of royal jelly on the appearance and development of IRE reticulo-sarcoma]. *Pathologica* 58 (865): 309-315.
43. DUTAU, G; RANCE, F (2009) Honey and honey-product allergies. *Revue Francaise D Allergologie* 49 (6): S16-S22.
44. DZOPALIC, T; VUCEVIC, D; TOMIC, S; DJOKIC, J; CHINO, I; COLIC, M (2011) 3,10-Dihydroxy-decanoic acid, isolated from royal jelly, stimulates Th1 polarising capability of human monocyte-derived dendritic cells. *Food Chemistry* 126 (3): 1211-1217.
45. EL NEKEETY, A A; EL KHOLY, W; ABBAS, N F; EBAID, A; AMRA, H A; ABDEL-WAHHAB, M A (2007) Efficacy of royal jelly against the oxidative stress of fumonisin in rats. *Toxicon* 50 (2): 256-269.
46. ELNAGAR, S (2010) Royal jelly counteracts bucks' "summer infertility". *Anim.Repr.Sci.* 121: 174-180.

47. EREM, C; DEGER, O; OVALI, E; BARLAK, Y (2006) The effects of royal jelly on autoimmunity in Graves' disease. *Endocrine* 30 (2): 175-183.
48. EUROPEAN PARLIAMENT AND COUNCIL (2007) REGULATION (EC) No 1924/2006 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 20 December 2006 on nutrition and health claims made on foods. *Official Journal of the European Union* L 404: L 12-3-L 12/17.
49. FANG, E; ZHOU, H; XU, H; XING, M (1994) Antiulcer effects of 10-hydroxy-2-decenoic acid in rats. *Zhongguo Yaolixue Tongbao* 10 (2): 9-42.
50. FATEEVA, E M; ROSHAL, L (1962) [Use of the preparation bee milk in children with chronic disorders of nutrition]. *Pediatrriia*. 41: 15-19.
51. FINKE, M D (2005) Nutrient composition of bee brood and its potential as human food. *Ecology of Food and Nutrition* 44 (4): 257-270.
52. FONTANA, R; MENDES, M A; DE SOUZA, B M; KONNO, K; CESAR, L M M; MALASPINA, O; PALMA, M S (2004) Jelleines: a family of antimicrobial peptides from the Royal Jelly of honeybees (*Apis mellifera*). *Peptides* 25 (6): 919-928.
53. FONTANA, R; MENDES, M A; DE SOUZA, B M; KONNO, K; CESAR, L M M; MALASPINA, O; PALMA, M S (2004) Jelleines: a family of antimicrobial peptides from the Royal Jelly of honeybees (*Apis mellifera*) 110. *Peptides* 25 (6): 919-928.
54. FOSSATI, C (1972) Rassegne sintetiche di terapia. Sulle possibilità terapeutiche della "gelatina reale"[Therapeutic possibilities of royal jelly]. *Clinica Terapeutica* 62 (4): 377-387.
55. FUJII, A (1995) Pharmacological effects of royal jelly 1043. *Honeybee Science* 16 (3): 97-104.
56. FUJIWARA, S; IMAI, J; FUJIWARA, M; YAESHIMA, T; KAWASHIMA, T; KOBAYASHI, K (1990) A potent antibacterial protein in royal jelly. Purification and determination of the primary structure of royalisin. *Journal of Biological Chemistry* 265 (19): 11333-11337.
57. FUJIWARA, S; IMAI, J; FUJIWARA, M; YAESHIMA, T; KAWASHIMA, T; KOBAYASHI, K (1990) A potent antibacterial protein in royal jelly. Purification and determination of the primary structure of royalisin. *J.Biol.Chem.* 265 (19): 11333-11337.
58. FUJIWARA, S; IMAI, J; FUJIWARA, M; YAESHIMA, T; KAWASHIMA, T; KOBAYASHI, K (1990) A potent antibacterial protein in royal jelly. Purification and determination of the primary structure of royalisin 220. *Journal of Biological Chemistry* 265 (19): 11333-11337.
59. FURUKAWA, S (2008) Stimulatory Effects of Royal Jelly on the Generation of Neuronal and Glial Cells - Expectation of Protection Against Some Neurological Disorders. *Foods and Food Ingredients J.Jpn* 213 (7)
60. GALAN, M F (1957) [Royal jelly as a coadjuvant in the therapy of degenerative rheumatism.]. *Medicina Espanola* 37 (219): 524-531.
61. GASIC, S; VUCEVIC, D; VASILJIC, S; ANTUNOVIC, M; CHINOU, I; COLIC, M (2007) Evaluation of the immunomodulatory activities of royal jelly components in vitro 36. *Immunopharmacology and Immunotoxicology* 29 (3-4): 521-536.
62. GIMBEL, N S; THRELKELD, R; FARRIS, W (1962) Epithelization in experimental burn blisters, *In Artz, C P (ed.) Research in Burns*, Am. Inst. Biol. Sci. and Blackwell Scientific Publication; Oxford, GB; pp 311-314.
63. GIORDANO, A; TRENTA, A; MAZZA, L (1959) [Research on the eventual radioprotective action of royal jelly on the mouse. Experimental contribution]. *Radiobiologia, Radioterapia e Fisica Medica* 14: 423-439.
64. GONNARD, P; N'GUYEN, C C (1957) [Action of royal jelly on oxygen consumption in tissues in vitro.]. *Annales pharmaceutiques francaises* 15 (6): 383-393.

65. GRAD, B; KRAL, V A; BERENSON, J (1961) Toxic and protective effects of royal jelly in normal and diseased mice. *Canadian journal of medical sciences* 39: 461-476.
66. GUO, H; KOUZUMA, Y; YONEKURA, M (2005) Isolation and properties of antioxidative peptides from water-soluble royal jelly protein hydrolysate. *Food Science and Technology Research* 11 (2): 222-230.
67. GUO, H; KOUZUMA, Y; YONEKURA, M (2009) Structures and properties of antioxidative peptides derived from royal jelly protein. *Food Chemistry* 113 (1): 238-245.
68. GUO, H; SAIGA, A; SATO, M; MIYAZAWA, I; SHIBATA, M; TAKAHATA, Y; MORIMATSU, F (2007) Royal jelly supplementation improves lipoprotein metabolism in humans. *JOURNAL OF NUTRITIONAL SCIENCE AND VITAMINOLOGY* 53 (4): 345-348.
69. GYUZUKINA, E; DIMITRIEVA, N (1993) Efektivnost preparata nativnovo pchelnovo molokchkd adsorbirovannovo na laktose m,r kandiddoznoi infektzii u nedonoshanich novorodenich. *Apiterapia sevodnja* (2): 23-26.
70. GYUZUKINA, E; DIMITRIEVA, N (1998) O srokah priminenia matochnova molochka u prejdevtremenno rojdenich detei. *Apiterapia sevodnja* (6): 85-87.
71. GYUZUKINA, E; DIMITRIEVA, N (1998) O srokah priminenia matochnova molochka u prejdevtremenno rojdenich detei. *Apiterapia sevodnja* (6): 85-87.
72. HASHIMOTO, M; KANDA, M; IKENO, K; HAYASHI, Y; NAKAMURA, T; OGAWA, Y; FUKUMITSU, H; NOMOTO, H; FURUKAWA, S (2005) Oral administration of royal jelly facilitates mRNA expression of glial cell line-derived neurotrophic factor and neurofilament H in the hippocampus of the adult mouse brain. *Bioscience Biotechnology and Biochemistry* 69 (4): 800-805.
73. HASSAN, A (2009) Effect of royal jelly on sexual efficiency in adult male rats. *Iraq J.Vet.Sci.* 23: 155-160.
74. HATTORI, N; NOMOTO, H; FUKUMITSU, H; MISHIMA, S; FURUKAWA, S (2007) AMP N1-oxide Potentiates Astrogenesis by Cultured Neural Stem/Progenitor Cells Through STAT3 Activation. *Biomedical Research-Tokyo* 28 (6): 295-299.
75. HATTORI, N; NOMOTO, H; FUKUMITSU, H; MISHIMA, S; FURUKAWA, S (2007) Royal jelly and its unique fatty acid, 10-hydroxy-trans-2-decenoic acid, promote neurogenesis by neural stem/progenitor cells in vitro. *Biomedical Research-Tokyo* 28 (5): 261-266.
76. HATTORI, N; NOMOTO, H; FUKUMITSU, H; MISHIMA, S; FURUKAWA, S (2007) Royal jelly-induced neurite outgrowth from rat pheochromocytoma PC12 cells requires integrin signal independent of activation of extracellular signal-regulated kinases. *Biomedical Research-Tokyo* 28 (3): 139-146.
77. HATTORI, N; NOMOTO, H; FUKUMITSU, H; MISHIMA, S; FURUKAWA, S (2010) AMP N-1-oxide, a unique compound of royal jelly, induces neurite outgrowth from PC12 cells via signaling by protein kinase A independent of that by mitogen-activated protein kinase. *Evidence-based complementary and alternative medicine* 7 (1): 63-68.
78. HATTORI, N; NOMOTO, H; MISHIMA, S; INAGAKI, S; GOTO, M; SAKO, M; FURUKAWA, S (2006) Identification of AMP N-1-oxide in royal jelly as a component neurotrophic toward cultured rat pheochromocytoma PC12 cells. *Bioscience Biotechnology and Biochemistry* 70 (4): 897-906.
79. HENSCHLER, D (1956) [Identification of choline esters in biological material, especially acetylcholine in royal jelly of bee]. *Hoppe-Seyler's Zeitschrift für physiologische Chemie* 305 (1): 34-41.
80. HIDAKA, S; OKAMOTO, Y; UCHIYAMA, S; NAKATSUMA, A; HASHIMOTO, K; OHNISHI, S T; YAMAGUCHI, M (2006) Royal jelly prevents osteoporosis in rats: Beneficial effects in ovariectomy model and in bone tissue culture model. *Evidence-based complementary and alternative medicine* 3 (3): 339-348.
81. HINGLAIS, H; HINGLAIS, M; GAUTHERIE, J (1956) [Hormonal study of royal jelly; research on the gonadotrophic principles and substances of estrogenic action]. *Comptes rendus des Séances de l'Academie des Sciences* 242 (20): 2482-2483.

82. HINGLAIS, H; HINGLAIS, M; GAUTHERIE, J (1956) [Research on the anabolic properties of royal jelly; experiments in the rat]. *C.R.Soc.Biol.* 150 (12): 2130-2131.
83. HINGLAIS, H; HINGLAIS, M; GAUTHERIE, J; LANGLANDE, M (1955) [Study of the bactericidal and antibiotic effect of royal jelly on Koch bacillus]. *Annales de l'Institut Pasteur* 89 (6): 684-686.
84. HUSEIN, M Q; HADDAD, S G (2006) A new approach to enhance reproductive performance in sheep using royal jelly in comparison with equine chorionic gonadotropin. *Animal Reproduction Science* 93 (1-2): 24-33.
85. HUSEIN, M Q; KRIDLI, R T (2002) Reproductive responses following royal jelly treatment administered orally or intramuscularly into progesterone-treated Awassi ewes. *Animal Reproduction Science* 74 (1-2): 45-53.
86. IKEDA, Y; WASHIZUKA, M; FURUICHI, H; FUKUDA, Y; KUWABARA, Y (1996) Stress and royal jelly. *Honeybee Science* 17 (3): 103-110.
87. ILIASH, N (1962) Primenenie preparata matochnoe molochko pri narushenie pitanii u detei grudnovo vozrasti. *Inform.Bulletin o matochnoe molochko, Rjazan* (3): 50-53.
88. INOUE, S; KOYA-MIYATA, S; USHIO, S; IWAKI, K; IKEDA, M; KURIMOTO, M (2003) Royal Jelly prolongs the life span of C3H/HeJ mice: correlation with reduced DNA damage. *Experimental gerontology* 38 (9): 965-969.
89. IZAR, G (1957) [Honey & royal jelly in therapeutic use.]. *Minerva medica* 48 (54): 2323-2327.
90. IZUTA, H; CHIKARAISHI, Y; SHIMAZAWA, M; MISHIMA, S; HARA, H (2009) 10-Hydroxy-2-decenoic Acid, a Major Fatty Acid from Royal Jelly, Inhibits VEGF-induced Angiogenesis in Human Umbilical Vein Endothelial Cells. *Evidence-based complementary and alternative medicine* 6 (4): 489-494.
91. JAMNIK, P; GORANOVIC, D; RASPOR, P (2006) Antioxidative action of royal jelly in yeast *Saccharomyces cerevisiae*. *Febs Journal* 273: 300-301.
92. JAMNIK, P; GORANOVIC, D; RASPOR, P (2007) Antioxidative action of royal jelly in the yeast cell. *Experimental gerontology* 42 (7): 594-600.
93. JOKSIMOVIC, A; STANKOVIC, D; JOSKIMOVIC, I; MOLNAR, S; JOKSIMOVIC, S (2011) Royal jelly as supplement for young football players. *Sport Science* 1: 62-67.
94. KACZOR, M; KOLTEK, A; MATUSZEWSKI, J (1962) [Effect of roya lejly on blood lipids in atherosclerosis]. *Polski Tygodnik Lekarski* 17: 1140-1144.
95. KAFTANOGLU, O; TANYELI, A (1997) The use of royal jelly during treatment of childhood malignancies, *Bee Products.Properties, Applications, and Apitherapy*: pp 179-183.
96. KAMAKURA, M (2002) Signal transduction mechanism leading to enhanced proliferation of primary cultured adult rat hepatocytes treated with royal jelly 57kDa protein. *Journal of Biochemistry* 132 (6): 911-919.
97. KAMAKURA, M; MITANI, N; FUKUDA, T; FUKUSHIMA, M (2001) Antifatigue effect of fresh royal jelly in mice. *JOURNAL OF NUTRITIONAL SCIENCE AND VITAMINOLOGY* 47 (6): 394-401.
98. KAMAKURA, M; SUENOBU, N; FUKUSHIMA, M (2001) Fifty-seven-kDa protein in royal jelly enhances proliferation of primary cultured rat hepatocytes and increases albumin production in the absence of serum. *Biochemical and Biophysical Research Communications* 282 (4): 865-874.
99. KARACA, T; BAYIROGLU, F; YORUK, M; KAYA, M S; USLU, S; COMBA, B; MIS, L (2010) Effect of royal jelly on experimental colitis induced by acetic acid and alteration of mast cell distribution in the colon of rats. *European Journal of Histochemistry* 54 (4): 193-196.
100. KHATTAB, M M; RADWAN, A A; AFIFI, E A (1989) Physiological effect of royal jelly on female reproductive capacity in rabbits.: 70-73.

101. KIM, J; KIM, Y; YUN, H; PARK, H; KIM, S Y; LEE, K G; HAN, S M; CHO, Y (2010) Royal jelly enhances migration of human dermal fibroblasts and alters the levels of cholesterol and sphinganine in an in vitro wound healing model. *Nutrition Research and Practice* 4 (5): 362-368.
102. KIM, J K; SON, J H; OH, H S (1989) Analysis of organic acids in honey and royal jelly. *Korean Journal of Apiculture* 4 (2): 105-111.
103. KIM, J-G; SON, J-H (1996) The quantity of superoxide dismutase (SOD) in fresh royal jelly. *Korean Journal of Apiculture* 11 (1): 8-12.
104. KIMURA, M; KIMURA, Y; TSUMURA, K; OKIHARA, K; SUGIMOTO, H; YAMADA, H; YONEKURA, M (2003) 350-kDa royal jelly glycoprotein (apisin), which stimulates proliferation of human monocytes, bears the beta 1-3galactosylated N-glycan: Analysis of the N-glycosylation site. *Bioscience, Biotechnology and Biochemistry* 67 (9): 2055-2058.
105. KIMURA, Y; KAJIYAMA, S; KANAEDA, J; IZUKAWA, T; YONEKURA, M (1996) N-linked sugar chain of 55-kDa royal jelly glycoprotein. *Bioscience, Biotechnology and Biochemistry* 60 (12): 2099-2102.
106. KIMURA, Y; MIYAGI, C; KIMURA, M; NITODA, T; KAWAI, N; SUGIMOTO, H (2000) Structural features of N-glycans linked to royal jelly glycoproteins: structures of high-mannose type, hybrid type, and biantennary type glycans. *Bioscience, Biotechnology and Biochemistry* 64 (10): 2109-2120.
107. KIMURA, Y; TSUMURA, K; KIMURA, M; OKIHARA, K; SUGIMOTO, H; YAMADA, H (2003) First evidence for occurrence of Gal beta 1-3GlcNAc beta 1-4Man unit in N-glycans of insect glycoprotein: beta 1-3Gal and beta 1-4GlcNAc transferases are involved in N-glycan processing of royal jelly glycoproteins. *Bioscience, Biotechnology and Biochemistry* 67 (8): 1852-1856.
108. KIMURA, Y; WASHINO, N; YONEKURA, M (1995) N-linked sugar chains of 350-kDa royal jelly glycoprotein. *Bioscience, Biotechnology and Biochemistry* 59 (3): 507-509.
109. KODAI, T; UMEBAYASHI, K; NAKATANI, T; ISHIYAMA, K; NODA, N (2007) Compositions of royal jelly II. Organic acid glycosides and sterols of the royal jelly of honeybees (*Apis mellifera*). *Chemical & Pharmaceutical Bulletin* 55 (10): 1528-1531.
110. KOHGUCHI, M; INOUE, S; USHIO, S; IWAKI, K; IKEDA, M; KURIMOTO, M (2004) Effect of royal jelly diet on the testicular function of hamsters. *Food Science and Technology Research* 10 (4): 420-423.
111. KOHNO, K; OKAMOTO, I; SANO, O; ARAI, N; IWAKI, K; IKEDA, M; KURIMOTO, M (2004) Royal jelly inhibits the production of proinflammatory cytokines by activated macrophages. *Bioscience Biotechnology and Biochemistry* 68 (1): 138-145.
112. KOYA-MIYATA, S; OKAMOTO, I; USHIO, S; IWAKI, K; IKEDA, M; KURIMOTO, M (2004) Identification of a collagen production-promoting factor from an extract of royal jelly and its possible mechanism. *Bioscience Biotechnology and Biochemistry* 68 (4): 767-773.
113. KRAMER, K; CHILDS, C N; SPIERS, R; JACOBS, R (1982) Purification of insulin-like peptides from insect haemolymph and royal jelly. *Insect Biochem* 12: 91-98.
114. KRAMER, K J; TAGER, H S; CHILDS, C N; SPEIRS, R D (1977) Insulin-like hypoglycemic and immunological activities in honeybee royal jelly. *J.Insect Physiol* 23 (2): 293-295.
115. KRELL, R (1996) *Value-added products from beekeeping*. FAO Food and Agriculture Organization of the United Nations Roma; 409 pp
116. KRELL, R (1996) *Value-added products from beekeeping*. FAO Food and Agriculture Organization of the United Nations Roma; 409 pp
117. KRELL, R (1996) *Value-added products from beekeeping*. FAO Food and Agriculture Organization of the United Nations Roma; 409 pp
118. KRIDL, R T; AL KHETIB, S S (2006) Reproductive responses in ewes treated with eCG or increasing doses of royal jelly. *Animal Reproduction Science* 92 (1-2): 75-85.



119. KRIDL, R T; HUSEIN, M Q; HUMPHREY, W D (2003) Effect of royal jelly and GnRH on the estrus synchronization and pregnancy rate in ewes using intravaginal sponges. *Small Ruminant Research* 49 (1): 25-30.
120. KRYLOV, V; AGAFONOV, A; KRIVTSOV, N; LEBEDEV, V; BURIMISTROVA, L; OSHEVENSKI, L; SOKOLSKI, S (2007) Royal jelly, *In* Russian academy of agriculture; Scientific institute of beekeeping; Nijnegorod University; Russian ministry of education and science (eds) Moscow; pp 122-124.
121. KRYLOV, V; AGAFONOV, A; KRIVTSOV, N; LEBEDEV, V; BURIMISTROVA, L; OSHEVENSKI, L; SOKOLSKI, S (2007) Royal jelly, *In* Russian academy of agriculture; Scientific institute of beekeeping; Nijnegorod University; Russian ministry of education and science (eds) Moscow; pp 126-127.
122. KRYLOV, V; AGAFONOV, A; KRIVTSOV, N; LEBEDEV, V; BURIMISTROVA, L; OSHEVENSKI, L; SOKOLSKI, S (2007) *Theory and agents of apitherapy (in Russian)*. Moscow
123. KRYLOV, V; AGAFONOV, A; KRIVTSOV, N; LEBEDEV, V; BURIMISTROVA, L; OSHEVENSKI, L; SOKOLSKI, S (2007) *Theory and agents of apitherapy (in Russian)*. Moscow
124. KRYLOV, V; SOKOLSKII C. (2000) *Royal jelly (in Russian)*. Agroprompoligrafist Krasnodar; 214 pp
125. KRYLOV, V; SOKOLSKII C. (2000) *Royal jelly (in Russian)*. Agroprompoligrafist Krasnodar; 214 pp
126. KURKURE, N V; KOGNOLE, S M; PAWAR, S P; GANORKAR, A G; BHANDARKAR, A G; INGLE, V C; KALOREY, D R (2000) Effect of royal jelly as immunomodulator in chicks. *Journal of Immunology & Immunopathology* 2 (1/2): 84-87.
127. KUZINA, N G (1987) [Action of apilak on the electrolyte and catecholamine content of the wall of arterial vessels at different levels of systemic arterial pressure]. *Farmakologija i Toksikologija* 50 (3): 46-49.
128. LAKIN, A (1993) Royal jelly and its efficacy. *International Journal of Alternative and Complementary Medicine* 11 (10): 19-22.
129. LAKIN, A (1993) Royal jelly and its efficacy. *International Journal of Alternative and Complementary Medicine* 11 (10): 19-22.
130. LAKIN, A (1993) Royal jelly and its efficacy. *International Journal of Alternative and Complementary Medicine* 11 (10): 19-22.
131. LANGLADE, H; HINGLAIS, H; HINGLAIS, M (1957) [Bactericidal activity of royal jelly on Koch bacillus; trial fractionation on active substance.]. *Annales de l'Institut Pasteur* 93 (2): 272-276.
132. LEBEDEVA, E (1959) K voprosu o primenenij matochnovo molochka u detei do goda (Use of royal jelly to treat hypertrophy of infants until one year old). *Inform.Buletin o matochnom moloke* 1: 6-19.
133. LEE, A; YEH, M; WEN, H; CHERN, J; LIN, J; HWANG, W (1999) The application of capillary electrophoresis on the characterization of protein in royal jelly. *Journal of Food and Drug Analysis* 7 (1): 73-82.
134. LERCKER, G; CABONI, M F; VECCHI, M A; SABATINI, A G; NANETTI, A (1992) Characterization of the main constituents of royal jelly. *Apicoltura* (8): 27-37.
135. LERCKER, G; CABONI, M F; VECCHI, M A; SABATINI, A G; NANETTI, A (1992) Characterization of the main constituents of royal jelly  
410. *Apicoltura* (8): 27-37.
136. LERCKER, G; CABONI, M F; VECCHI, M A; SABATINI, A G; NANETTI, A (1993) Caratterizzazione dei principali costituenti della gelatina reale. *Apicoltura* 8: 27-37.
137. LERCKER, G; CABONI, M F; VECCHI, M A; SABATINI, A G; NANETTI, A; PIANA, L (1985) Composizione della frazione glucidica della gelatina reale e della gelatina delle api operaie in relazione all'eta larvale. *Apicoltura* 1: 123-139.

138. LERCKER, G; CAPELLA, P; CONTE, L S; RUINI, F (1981) Components of royal jelly: I. Identification of the organic acids. *Lipids* 16 (12): 912-919.
139. LERCKER, G; CAPELLA, P; GIORDANI, G (1982) Components of royal jelly II: The lipid fractions hydrocarbons and sterols. *Journal of Apicultural Research* 21 (3): 178-184.
140. LERCKER, G; SAVIOLI, S; VECCHI, M A; SABATINI, A G; NANETTI, A; PIANA, L (1986) Carbohydrate determination of royal jelly by high resolution gas chromatography (HRGC). *Food Chemistry* 19: 255-264.
141. LERRER, B; ZINGER-YOSOVICH, K D; AVRAHAMI, B; GILBOA-GARBER, N (2007) Honey and royal jelly, like human milk, abrogate lectin-dependent infection-preceding *Pseudomonas aeruginosa* adhesion. *Isme Journal* 1 (2): 149-155.
142. LEUNG, R; HO, A; CHAN, J; CHOY, D; LAI, C K W (1997) Royal jelly consumption and hypersensitivity in the community. *Clinical and Experimental Allergy* 27: 333-336.
143. LEUNG, R; THIEN, F C K; BALDO, B; CZARNY, D (1995) Royal jelly-induced asthma and anaphylaxis: clinical characteristics and immunologic correlations 1214. *Journal of Allergy and Clinical Immunology* 96 (6, pt 1): 1004-1007.
144. LEUNG, R; THIEN, F C K; BALDO, B; CZARNY, D (1995) Royal jelly-induced asthma and anaphylaxis: clinical characteristics and immunologic correlations 1214. *Journal of Allergy and Clinical Immunology* 96 (6, pt 1): 1004-1007.
145. LEUNG, R; THIEN, F C K; BALDO, B; CZARNY, D (1995) Royal jelly-induced asthma and anaphylaxis: clinical characteristics and immunologic correlations 1214. *Journal of Allergy and Clinical Immunology* 96 (6, pt 1): 1004-1007.
146. LEWIS, R (2004) *The Infertility Cure: The Ancient Chinese Wellness Program for Getting Pregnant and Having Healthy Babies*. Little Brown and Company; 303 pp
147. LINDER, J (1963) Activity of royal jelly against various Trypanosomidae. *Journal of Apicultural Research* 2 (1): 71-72.
148. LIU, J R; YANG, Y C; SHI, L S; PENG, C C (2008) Antioxidant Properties of Royal Jelly Associated with Larval Age and Time of Harvest. *Journal of agricultural and food chemistry* 56 (23): 11447-11452.
149. LUDYANSKII, E A (1994) *Apitherapy 1231*. Poligrafist Vologda, Russia
150. LUPACHEV, V (1965) Apilac for the healing of coronary arteriosklerosis. Ryazan University Ryazan
151. MAGDALENA, M (2010) Effect of royal jelly on breast infant with dystrophy and maldevelopment, *In Apimondia* (ed.) *20th Apimondia International Beekeeping Congress in Bukarest, Romania*: pp 583-585.
152. MAJTAN, J; KOVACOVA, E; BILIKOVA, K; SIMUTH, J (2006) The immunostimulatory effect of the recombinant apalbumin 1-major honeybee royal jelly protein-on TNF alpha release. *International immunopharmacology* 6 (2): 269-278.
153. MAJTAN, J; KUMAR, P; MAJTAN, T; WALLS, A F; KLAUDINY, J (2010) Effect of honey and its major royal jelly protein 1 on cytokine and MMP-9 mRNA transcripts in human keratinocytes. *Experimental Dermatology* 19 (8): E73-E79.
154. MALOSSI, C; GRANDI, F (1956) Osservazioni sulla gelatina reale nell'alimentazione degli immaturi. Atti del 10 convegno nazionale per lo studio dell' applicazione dei prodotti delle api nel campo medico-biologico, Bologna, Italy: pp 130-133.
155. MALY, E; PACENOVSKA, M (1966) [Successful treatment of warts by royal jelly]. *Ceskoslovenska Dermatologie* 41 (1): 36-39.
156. MANNOOR, M K; SHIMABUKURO, I; TSUKAMOTOA, M; WATANABE, H; YAMAGUCHI, K (2009) Honeybee royal jelly inhibits autoimmunity in SLE-prone NZB x NZW F1 mice. *Lupus* (1): 44-52.

157. MANNOOR, M K; TSUKAMOTO, M; WATANABE, H; YAMAGUCHI, K; SATO, Y (2008) The efficacy of royal jelly in the restoration of stress-induced disturbance of lymphocytes and granulocytes  
43  
77729. *Biomedical Research-India* 19 (2): 69-77.
158. MARKO, P; PECH'AN, I; VITTEK, J (1964) SOME PHOSPHORUS COMPOUNDS IN ROYAL JELLY. *Nature* 202: 188-189.
159. MARUYAMA, H; YOSHIDA, C; TOKUNAGA, K; ARAKI, Y; MISHIMA, S (2005) The effect of a peptide (Ile-Val-Tyr) derived from royal jelly treated with protease on blood pressure of spontaneously hypertensive rat. *Journal of the Japanese Society for Food Science and Technology Nippon Shokuhin Kagaku Kogaku Kaishi* 52 (10): 491-494.
160. MATSUBARA, T; SUGIMOTO, H; AIDA, M (2008) A Theoretical Insight into the Interaction of Fatty Acids Involved in Royal Jelly with the Human Estrogen Receptor beta. *Bulletin of the Chemical Society of Japan* 81 (10): 1258-1266.
161. MATSUI, T; YUKIYOSHI, A; DOI, S; ISHIKAWA, H; MATSUMOTO, K (2006) Enzymatic hydrolysis of ethanol-insoluble proteins from royal jelly and identification of ACE inhibitory peptides. *Journal of the Japanese Society for Food Science and Technology Nippon Shokuhin Kagaku Kogaku Kaishi* 53 (4): 200-206.
162. MATSUI, T; YUKIYOSHI, A; DOI, S; SUGIMOTO, H; YAMADA, H; MATSUMOTO, K (2002) Gastrointestinal enzyme production of bioactive peptides from royal jelly protein and their antihypertensive ability in SHR. *JOURNAL OF NUTRITIONAL BIOCHEMISTRY* 13 (2): 80-86.
163. MATSUI, T; YUKIYOSHI, A; DOI, S; SUGIMOTO, H; YAMADA, H; MATSUMOTO, K (2002) Gastrointestinal enzyme production of bioactive peptides from royal jelly protein and their antihypertensive ability in SHR. *JOURNAL OF NUTRITIONAL BIOCHEMISTRY* 13 (2): 80-86.
164. MATSUKA, M (1993) Content of benzoic acid in royal jelly and propolis. *Honeybee Science* 14 (2): 79-80.
165. MELLIU, E; CHINO, I (2005) Chemistry and bioactivity of royal jelly from Greece. *J.Agricultural & Food Chemistry* 53: 8987-8992.
166. MISHIMA, S; SUZUKI, K M; ISOHAMA, Y; KURATSU, N; ARAKI, Y; INOUE, M; MIYATA, T (2005) Royal jelly has estrogenic effects in vitro and in vivo. *Journal of Ethnopharmacology* 101 (1-3): 215-220.
167. MIYAMOTO, M; TSUMURA, K; KIMURA, M; OKIHARA, S; SUGIMOTO, H; YAMADA, H; KIMURA, Y (2004) N-glycans bearing beta-1,3-galactosyl residue in royal jelly glycoproteins. *Glycobiology* 14 (11): 241.
168. MONTEVERDI, T; REITANO, S (1972) Eutrophic effect of a "natural food" (queen honeybee larvae) in a group of psychiatric patients. *Minerva Dietologica* 12 (4): 133-144.
169. MORMONE, V; NUNZIATA, B; SPINA, D (1959) [Variations of some metabolic indices after the administration, by parenteral route, of royal jelly]. *La Clinica pediatrica* 41: 1143-1149.
170. MOUTSATSOU, P; PAPOUTSI, Z; KASSI, E; HELDRING, N; ZHAO, C; TSIAPARA, A; MELLIU, E; CHROUSOS, G; CHINO, I; KARSHIKOFF, A; NILSSON, L; DAHLMAN-WRIGHT, K (2010) Fatty Acids Derived from Royal Jelly Are Modulators of Estrogen Receptor Functions. *Plos One* 5: e15594.
171. MÜNSTEDT, K; BARGELLO, M; HAUENSCHILD, A (2009) Royal Jelly Reduces the Serum Glucose Levels in Healthy Subjects. *J Med Food* 12: 1170-1172.
172. MÜNSTEDT, K; BARGELLO, M; HAUENSCHILD, A (2009) Royal jelly and its lack of immediate influence on human serum fructose and serum lipids. *Journal of ApiProduct and ApiMedical Science* 1 (3): 90-91.
173. NAGAI, T (2001) [Properties and functions of gluconic acid and its salts]. *Honeybee Science* 22 (4): 171-174.
174. NAGAI, T; INOUE, R; SUZUKI, N; NAGASHIMA, T (2006) Antioxidant properties of enzymatic hydrolysates from royal jelly. *Journal of Medicinal Food* 9 (3): 363-367.

175. NAGAI, T; SAKAI, M; INOUE, R; INOUE, H; SUZUKI, N (2001) Antioxidative activities of some commercially honeys, royal jelly, and propolis. *Food Chemistry* 75 (2): 237-240.
176. NAKAYA, M; ONDA, H; SASAKI, K; YUKIYOSHI, A; TACHIBANA, H; YAMADA, K (2007) Effect of royal jelly on bisphenol A-induced proliferation of human breast cancer cells. *Bioscience Biotechnology and Biochemistry* 71 (1): 253-255.
177. NARITA, Y; NOMURA, J; OHTA, S; INOH, Y; SUZUKI, K M; ARAKI, Y; OKADA, S; MATSUMOTO, I; ISOHAMA, Y; ABE, K; MIYATA, T; MISHIMA, S (2006) Royal jelly stimulates bone formation: Physiologic and nutrigenomic studies with mice and cell lines. *Bioscience Biotechnology and Biochemistry* 70 (10): 2508-2514.
178. NARUMI, S (2004) Honeybee brood as a nutritional food. *Honeybee Science* 25 (3): 119-124.
179. NOMURA, M; MARUO, N; ZAMAMI, Y; TAKATORI, S; DOI, S; KAWASAKI, H (2007) Effect of long-term treatment with royal jelly on insulin resistance in Otsuka Long-Evans Tokushima Fatty (OLETF) rats 82. *Yakugaku Zasshi-Journal of the Pharmaceutical Society of Japan* 127 (11): 1877-1882.
180. OKA, H; EMORI, Y; KOBAYASHI, N; HAYASHI, Y; NOMOTO, K (2001) Suppression of allergic reactions by royal jelly in association with the restoration of macrophage function and the improvement of Th1/Th2 cell responses. *International immunopharmacology* 1 (3): 521-532.
181. OKAMOTO, I; TANIGUCHI, Y; KUNIKATA, T; KOHNO, K; IWAKI, K; IKEDA, M; KURIMOTO, M (2003) Major royal jelly protein 3 modulates immune responses in vitro and in vivo. *Life sciences.Pt.2: Biochemistry, general and molecular biology* 73 (16): 2029-2045.
182. OKUDA, H; KAMEDA, K; MORIMOTO, C; MATSUURA, Y; CHIKAKI, M; MING, J (1998) Studies on insulin-like substances in royal jelly and other substances in royal jelly which inhibit angiotensin-converting enzyme. *Honeybee Science* 19 (1): 9-14.
183. ORIBE, E; ARIOKA, T; FUKUDA, K; TATEFUJI, T; HASHIMOTO, K; MAEDA, K (2010) Moisturizing effect of royal jelly extract and its mechanism on skin. *Journal of Dermatology* 37: 77.
184. ORSOLIC, N; SACASES, F; DU SERT, P P; BASIC, I (2007) Antimetastatic ability of honey bee products. *Periodicum Biologorum* 109 (2): 173-180.
185. ORSOLIC, N; TERZIC, S; SVER, L; BASIC, I (2005) Honey-bee products in prevention and/or therapy of murine transplantable tumours. *Journal of the Science of Food and Agriculture* 85: 363-370.
186. OSINTZEVA, L; EFANOVA, N; KABISHEVA, V (2009) Drone brood homogenate for dog feeding (Russian). *Pcelovodstvo* (10)
187. PAVERO, A; CAVIGLIA, E (1957) [Royal jelly and its applications in therapy.]. *Archivio "E.Maragliano" di patologia e clinica* 13 (4): 1023-1033.
188. PEACOCK, S; MURRAY, V; TURTON, C (1995) Respiratory distress and royal jelly. *British Medical Journal* 311 (7018): 1472.
189. PEACOCK, S; MURRAY, V; TURTON, C (1995) Respiratory distress and royal jelly. *British Medical Journal* 311 (7018): 1472.
190. PEACOCK, S; MURRAY, V; TURTON, C (1995) Respiratory distress and royal jelly. *British Medical Journal* 311 (7018): 1472.
191. PEJCEV, P; BOJADZIEV, S; MAROVSKI, T (1965) [THE INFLUENCE OF ROYAL JELLY ON THE COURSE OF RADIATION SICKNESS IN WHITE RATS]. *Folia Med.(Plovdiv.)* 48: 69-73.
192. PEJTSCHIEFF, P; BELEWA-STAJKOWA, P; ATANASSOFF, N (1975) Einfluss des Weiselfuttersaftes auf den Sauerstoffverbrauch und die Aktivität der Adenosintriphosphatase in den Geweben weisser Mäuse *Der XXV. Internationale Bienenzüchterkongress Grenoble - Frankreich 1975*, Apimondia-Verlag; Bukarest, Rumänien; pp 248-251.

193. POPESCU, M P; ALEXANDRA, D; POPESCU, M (1987) [Royal jelly and its use in ophthalmology]. *Rev.Chir Oncol.Radiol.O.R.L Oftalmol.Stomatol.Ser.Oftalmol.* 31 (1): 53-56.
194. POPLAWSKY, A (2008) Food for Thought: Royal Jelly for the People. *The Central Sulcus* 4: 3-4.
195. POPOVA, A (1960) K voprosu o primenenii preparata matochnoe molochko pri kishechnom infantilisme. *Inform Bulletin Nauchn.Instituta Ribnoe* 4: 32-36.
196. PROHODA, I (2009) Apilarval products for functional nutrition. *Pcelovodstvo* (7)
197. PROSPERI, P; RAGAZZINI, F (1956) [Clinical uses of royal jelly in pediatrics]. *Rivista di Clinica Pediatrica* 58 (3): 319-332.
198. QUADRI, S (1956) [Use of royal jelly in dystrophy in young infants]. *Clinica Otorinolaringoiatrica* 38 (9): 686-690.
199. RAGAB, S S; IBRAHIM, M K (1999) Evaluation of some chemical, antibacterial and biological properties of fresh and refrigerated royal jelly. *Egyptian Journal of Microbiology* 34 (1): 115-128.
200. REMBOLD, H; DIETZ, A (1965) Biologically active substances in royal jelly. *Vitamines and Hormones* 23: 359-383.
201. RONDININI, B (1956) [Effect of royal jelly on blood sugar in diabetics]. *Clinica Otorinolaringoiatrica* 38 (9): 703-706.
202. SABATINI, A G; MARCAZZAN, G; CABONI, M F; BOGDANOV, S; ALMEIDA-MURADIAN, L B (2009) Quality and standardisation of royal jelly. *JAAS* 1: 1-6.
203. SANO, O; KUNIKATA, T; KOHNO, K; IWAKI, K; IKEDA, M; KURIMOTO, M (2004) Characterization of royal jelly proteins in both Africanized and European honeybees (*Apis mellifera*) by two-dimensional gel electrophoresis. *Journal of agricultural and food chemistry* 52 (1): 15-20.
204. SARROUY, C; RAFFI, A; LEUTENEGER, M (1956) [Treatment of eight cases of severe infant hypotrophy by lyophilized extracts of royal jelly]. *Pediatric.* 11 (4): 409-412.
205. SAUERWALD, N; POLSTER, J; BENGSCHE, E; NIESSEN, L; VOGEL, R (1998) Combine antibacterial and antifungal properties of water soluble fraction of royal jelly. *Adv.Food Sci.* 20 (1/2): 52-56.
206. SAUTKIN, M (2010) Use of bee products in sport medicine, In Rakita, D; Krivtsov, N; Uzbekova, D G (eds) *Theoretical and practical basics of apitherapy (Russian)*, Roszdrav; Ryazan; pp 259-272.
207. SCHMIDT, J O; BUCHMANN, S L (1992) Other products of the hive. in: *The Hive and the Honey Bee* (Graham, J.M., Editor) Dadant & Sons, Hamilton, IL. *unknown*: 927-988.
208. SCHMITZOVA, J; KLAUDINY, J; ALBERT, S; SCHRODER, W; SCHRECKENGOST, W; HANES, J; JUDOVA, J; SIMUTH, J (1998) A family of major royal jelly proteins of the honeybee *Apis mellifera* L. *Cellular and Molecular Life Sciences* 54 (9): 1020-1030.
209. SERRA BONVEHI, J (1990) Studies on the proteins and free amino acids of royal jelly. *Anal.Bromatol.* 42 (2): 353-365.
210. SERRA BONVEHI, J (1991) Composition en sels minéraux et en vitamines de la gelée royale. *Bulletin Technique Apicole* 74 (18): 13-20.
211. SERRA BONVEHI, J (1992) Sugars, acidity and pH of royal jelly. *Anal.Bromatol.* 44 (1): 65-69.
212. SERRA BONVEHI, J; ESCOLA JORDA, R (1991) Studie über die mikrobiologische Qualität und bakteriostatische Aktivität des Weiselfuttersaftes (Gelée Royale): Beeinflussung durch organische Säuren. *Deutsche Lebensmittel-Rundschau* 87 (8): 256-260.
213. SERRA BONVEHI, J; ESCOLA JORDA, R (1991) Study of the microbiological quality and bacteriostatic activity of queen food (royal jelly): effect of organic acids. *Deutsche Lebensmittel-Rundschau* 87 (8): 256-529.

214. SHEN, X; LU, R; HE, G (1995) Effects of lyophilized royal jelly on experimental hyperlipaemia and thrombosis. *Zhonghua Yufang Yixue Zazhi* 29 (1): 27-29.
215. SHEN, X; LU, R; HE, G (1995) Effects of lyophilized royal jelly on experimental hyperlipaemia and thrombosis 1434. *Zhonghua Yufang Yixue Zazhi* 29 (1): 27-29.
216. SHINODA, M; NAKAJIN, S; OIKAWA; SATO, K; KAMOGAWA, A; AKIYAMA, Y (1978) Biochemical studies on vasodilatative factor in royal jelly, in Japanese, English Abstract. *Yakugaku Zasshi* 98: 139-145.
217. SHKENDEROV, S; IVANOV, T (1983) Pcelni Produkti, The Bee Products (in Bulgarian). *Zemizdat (Abstract in Honey bibliography)*: 1-238.
218. SIMSEK, N; KARADENIZ, A; BAYRAKTAROGLU, A G (2009) Effects of L-carnitine, Royal jelly and Pomegranate Seed on Peripheral Blood Cells in Rats. *Kafkas Universitesi Veteriner Fakultesi Dergisi* 15 (1): 63-69.
219. SIMÚTH, J (2001) Some properties of the main protein of honeybee (*Apis mellifera*) royal jelly. *Apidologie* 32 (1): 69-80.
220. SIMUTH, J; BILIKOVA, K (2004) Potential contribution of royal jelly proteins for health. *Honeybee Science* 25 (2): 53-62.
221. SIMUTH, J; BILIKOVA, K; KOVACOVA, E (2003) Royal jelly proteins as a tool for development of functional ingredients for health, *XXXVIII-th International Apicultural Congress*: pp Nr. 312.
222. SPIRIDONOV, N A; BAKANEVA, V F; NARIMANOV, A A; ARKHIPOV, V V (1989) Myotropic action and cytotoxicity of honey bee products 672. *Farmatsiya* 38 (4): 62-63.
223. SPULBER, E (1984) [Pulverizations of lyophilized royal jelly as an efficient method in the treatment of chronic diseases of the upper respiratory tract]. *Rev. Chir. Oncol. Radiol. O.R.L. Oftalmol. Stomatol. Otorinolaringol.* 29 (1): 59-66.
224. STOCKER, A (2003) Isolation and characterisation of substances from Royal Jelly. PhD Thesis; Université d'Orléans (France) Orléans (France); pp 1-202.
225. STOCKER, A; SCHRAMMEL, P; KETTRUP, A; BENGSCHE, E (2005) Trace and mineral elements in royal jelly and homeostatic effects. *Journal of Trace Elements in Medicine and Biology* 19 (2-3): 183-189.
226. SUZUKI, K M; ISOHAMA, Y; MARUYAMA, H; YAMADA, Y; NARITA, Y; OHTA, S; ARAKI, Y; MIYATA, T; MISHIMA, S (2008) Estrogenic activities of fatty acids and a sterol isolated from royal jelly 34 77757. *Evidence-based complementary and alternative medicine* 5 (3): 295-302.
227. SVER, L; ORSOLIC, N; TADIC, Z; NJARI, B; VALPOTIC, I; BASIC, I (1996) A royal jelly as a new potential immunomodulator in rats and mice. *Comparative Immunology, Microbiology and Infectious Diseases* 19 (1): 31-38.
228. SVER, L; ORSOLIC, N; TADIC, Z; NJARI, B; VALPOTIC, I; BASIC, I (1996) A royal jelly as a new potential immunomodulator in rats and mice. *Comparative Immunology, Microbiology and Infectious Diseases* 19 (1): 31-38.
229. SZANTO, E; GRUBER, D; SATOR, M; KNOGLER, W; HUBER, J C (1994) [Placebo-controlled study of melbrosia in treatment of climacteric symptoms]. *Wiener Medizinische Wochenschrift* 144 (7): 130-133.
230. TAKAHASHI, M; MATSUO, I; OHKIDO, M (1983) Contact dermatitis due to honeybee royal jelly. *Contact Dermatitis* 9 (6): 452-455.
231. TAKENAKA, T; YATSUNAMI, K; ECHIGO, T (1986) Changes in quality of royal jelly during storage. *Nippon Shokuhin Kogyo Gakkaishi* 33 (1): 1-7.

232. TAMURA, T; FUJII, A; KUBOYAMA, N (1987) Anti-tumor effects of royal jelly. *Nippon Yakurigaku Zasshi* 89 (2): 73-80.
233. TANIGUCHI, Y; KOHNO, K; INOUE, S; KOYA-MIYATA, S; OKAMOTO, I; ARAI, N; IWAKI, K; IKEDA, M; KURIMOTO, M (2003) Oral administration of royal jelly inhibits the development of atopic dermatitis-like skin lesions in NC/Nga mice. *International immunopharmacology* 3 (9): 1313-1324.
234. TARTAKOVSKAIA, A I (1966) [Apilak (royal jelly) in the therapy of trophic disorders of the cornea in eye burns]. *Vestnik Oftalmologii* 79 (1): 59-61.
235. TATSUHIKO, T; NAOKO, K; YUKO, H (2011) Application of the material of honeybee origin. Application of the cosmetic material of the honeybee origin (Japanese). *Frag J.* 30: 17-24.
236. TERADA, Y; NARUKAWA, M; WATANABE, T (2011) Specific Hydroxy Fatty Acids in Royal Jelly Activate TRPA1. *Journal of agricultural and food chemistry* 59 (6): 2627-2635.
237. TESTI, S; CECCHI, L; SEVERINO, M; MANFREDI, M; ERMINI, G; MACCHIA, D; CAPRETTI, S; CAMPI, P (2007) Severe anaphylaxis to royal jelly attributed to cefonicid. *Journal of investigational allergology & clinical immunology : official organ of the International Association of Asthmology (INTERASMA) and Sociedad Latinoamericana de Alergia e Inmunología* 17 (4): 281.
238. THRASYVOULOU, A T (1982) Biochemical and biological aspects of honey bee (*Apis mellifera* L.) larval food. The Pennsylvania State University. The Graduate School. Department of Entomology Pennsylvania, USA; pp 1-208.
239. TOKUNAGA, K; SUZUKI, K; YOSHIDA, C; MARUYAMA, H; FUTAMURA, Y; ARAKI, Y; MISHIMA, S (2003) Effect of royal jelly treated with protease on blood pressure in spontaneously hypertensive rats. *Journal of the Japanese Society for Food Science and Technology Nippon Shokuhin Kagaku Kogaku Kaishi* 50 (10): 457-462.
240. TOKUNAGA, K; SUZUKI, K M; YOSHIDA, C; MARUYAMA, H; FUTAMURA, Y; ARAKI, Y; MISHIMA, S (2004) Antihypertensive mechanism of royal jelly treated with protease in spontaneously hypertensive rats. *Journal of the Japanese Society for Food Science and Technology Nippon Shokuhin Kagaku Kogaku Kaishi* 51 (1): 34-37.
241. TOKUNAGA, K; YOSHIDA, C; SUZUKI, K; MARUYAMA, H; FUTAMURA, Y; ARAKI, Y; MISHIMA, S (2004) Antihypertensive effect of peptides from royal jelly in spontaneously hypertensive rats. *Biological & Pharmaceutical Bulletin* 27 (2): 189-192.
242. TOKUNAGA, K; YOSHIDA, C; SUZUKI, K; MARUYAMA, H; FUTAMURA, Y; ARAKI, Y; MISHIMA, S (2004) Antihypertensive effect of peptides from royal jelly in spontaneously hypertensive rats 882. *Biological & Pharmaceutical Bulletin* 27 (2): 189-192.
243. TOWNSEND, G; MORGAN, J; TOLNAI, S; HAZLETT, B; MORTON, H; SHUEL, R W (1960) Studies on the in vitro antitumor activity of fatty acids from royal jelly. *Cancer Research* 20: 503-510.
244. TOWNSEND, G F; MORGAN, J F; HAZLETT, B (1959) Activity of 10-hydroxydecanoic acid from royal jelly against experimental leukaemia and ascitic tumours. *Nature* 183 (4670): 1270-1271.
245. TOWNSEND, G F; MORGAN, J F; TOLNAI, S; HAZLETT, B; MORTON, H J; SHUEL, R W (1960) Studies on the in vitro antitumor activity of fatty acids. I. 10-Hydroxy-2-decanoic acid from royal jelly. *Cancer Research* 20: 503-510.
246. TRAJKOVIC, V (1961) [The role of royal jelly in carcinogenesis]. *Stud.Gen.(Berl)* 89: 343-352.
247. TSURUMA, Y; MARUYAMA, H; ARAKI, Y (2011) Effect of a Glycoprotein (Apisin) in Royal Jelly on Proliferation and Differentiation in Skin Fibroblast and Osteoblastic Cells. *Journal of the Japanese Society for Food Science and Technology-Nippon Shokuhin Kagaku Kogaku Kaishi* 58 (3): 121-126.
248. VALIUKIENE, K; CEREMNYCH, E; GAIGALIENE, B (1997) Effects of Apilac (royal jelly) on health, *35th Apimondia Congress in Anvers, Belgium*: pp 497.

249. VALIUKIENE, K; CEREMNYCH, E; GAIGALIENE, B (1997) Effects of Apilac (royal jelly) on health, *35th Apimondia Congress in Anvers, Belgium*: pp 497.
250. VASILEVA, M (1962) Primenenie preparata matochnoe molochko pri lechenie ditrofii u detei ranech vozrosti. *Inform.Bulletin o matochnoe molochko, Rjazan* (3): 54-58.
251. VECCHI, M A; SABATINI, A G; GRAZIA, L; TINI, V; ZAMBONELLI, C (1988) Il contenuto in vitamine come possibile elemento di caratterizzazione della gelatina reale. *Apicoltura* 4: 139-146.
252. VITTEK, J (1970) Isolation of the mucin binding glycoprotein from royal jelly of bee. *Biologia* 25 (9): 593-597.
253. VITTEK, J (1995) Effect of royal jelly on serum lipids in experimental animals and humans with atherosclerosis. *Experientia* 51 (9-10): 927-935.
254. VITTEK, J; HALMOS, J (1968) [Study of the remineralization of the rabbit bone wound in vivo using absorption roentgenography]. *Ceskoslovenska Stomatologie* 68 (1): 1-5.
255. VITTEK, J; JANCI, J (1968) *Vcelia materskaksieka*. Slov. vi. podoh., it. Bratislava
256. VITTEK, J; SLOMIANY, B (1984) Testosterone in royal jelly. *Cellular and Molecular Life Sciences* 40: 104-106.
257. VUCEVIC, D; MELLIOU, E; VASILIJIC, S; GASIC, S; IVANOVSKI, P; CHINO, I; COLIC, M (2007) Fatty acids isolated from royal jelly modulate dendritic cell-mediated immune response in vitro. *International immunopharmacology* 7 (9): 1211-1220.
258. WAGNER, H; DOBLER, I; THIEM, I (1970) [Effect of food-juice of the queen bee (royal jelly) on the peripheral blood and the survival rate of mice after whole body x-irradiation]. *Radiobiol.Radiother.(Berl)* 11 (3): 323-328.
259. WATANABE, K; SHINMOTO, H; KOBORI, M; TSUSHIDA, T; SHINOHARA, K; KANAEDA, J; YONEKURA, M (1996) Growth stimulation with honey royal jelly DIII protein of human lymphocytic cell lines in a serum-free medium. *Biotechnology Techniques* 10 (12): 959-962.
260. WEI, W; WEI, M; KANG, X J; DENG, H H; LU, Z H (2009) A novel method developed for acetylcholine detection in royal jelly by using capillary electrophoresis coupled with electrogenerated chemiluminescence based on a simple reaction. *Electrophoresis* 30 (11): 1949-1952.
261. WU, G; LI, Y; LIU, G (1991) The immunoregulative effect of royal jelly acid. *Zhongguo Yaoke Daxue Xuebao* 22 (2): 117-118.
262. XIAO, J; WANG, R; LI, S (1996) An active peptide inhibiting bacteria in the royal jelly of honey bee. *Acta Entomologica Sinica* 39 (2): 133-140.
263. XIAO, J W; WANG, R J; LI, S W (1996) An active peptide inhibiting bacteria in the royal jelly of honey bee. *Acta Entomologica Sinica* 39 (2): 133-140.
264. XU, D; MEI, X; XU, S (2002) The research of 10-hydroxy-2-decenoic acid on experiment hyperlipidemic rat. *Journal of Chinese medicinal materials* 25 (5): 346-347.
265. YAMADA, K; IKEDA, I; SUGAHARA, T; SHIRAHATA, S; MURAKAMI, H (1989) Screening of immunoglobulin production stimulating factor (IPSF) in foodstuffs using human-human hybridoma HB4C5 cells 784. *Agricultural and Biological Chemistry* 53 (11): 2987-2991.
266. YAMADA, K; IKEDE, I; MAEDA, M; SHIRAHATA, S; MURAKAMI, H (1990) Effect of immunoglobulin production stimulating factors in foodstuffs on immunoglobulin production of human lymphocytes. *Agricultural and Biological Chemistry* 54 (4): 1087-1089.
267. YANG, X Y; YANG, D S; WEI, Z; WANG, J M; LI, C Y; YE, H; LEI, K F; CHEN, X F; SHEN, N H; JIN, L Q; WANG, J G (2010) 10-Hydroxy-2-decenoic acid from Royal jelly: A potential medicine for RA. *Journal of Ethnopharmacology* 128 (2): 314-321.



268. YATSUNAMI, K; ECHIGO, T (1985) Antibacterial action of royal jelly. *Bulletin of the Faculty of Agriculture* (25): 13-22.
269. YONEKURA, M (1998) Characterization and physiological function of royal jelly proteins. *Honeybee Science* 19 (1): 15-22.
270. ZWEER, V (1962) Vlijanie preparata matochnoe molochko na povishenii laktatzii u rodilnach i vostonovlenie vesa u novorodenich. *Inform.Bulletin o matochnoe molochko, Rjazan* (3): 95-108.
271. ZWEER, V (1962) Vostonovlenie belkov i ich frakktiei v krovi rodilnitz posle patologicheskich krovopoter pri lechenie preparatom matochnoe molochko. *Inform.Bulletin o matochnoe molochko, Rjazan* (3): 75-85.
272. ZWEER, V (1974) Influence of apilac in climacterium syndrom. *Inform.Bulletin o matochnoe molochko, Rjazan* (4): 134-138.